Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases

ABSTRACT

The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.

RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/656,766, filed Jul. 21, 2017, which is a divisional application of U.S. patent application Ser. No. 14/196,047 filed Mar. 4, 2014, now U.S. Pat. No. 9,850,264, issued Dec. 26, 2017, which claims the benefit of U.S. Provisional Patent Application No. 61/773,773 filed Mar. 6, 2013, each of which are hereby incorporate by reference in their entireties and serve as the basis of a priority and/or benefit claim for the present application

BACKGROUND OF THE INVENTION 1. Field of the Invention

The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).

2. Summary of the Related Art

The formyl peptide receptor (FPR) family is involved in host defense against pathogens, but also in sensing internal molecules that may provide signals of cellular dysfunction. This family includes 3 members in humans and one member of this family FPR2 (also known as FPRL-1, ALXA4) is a G protein-coupled receptor that is expressed predominantly on inflammatory cells such as monocytes and neutrophils, as well as on T cells and has been shown to play a critical role in leukocyte trafficking during inflammation and human pathology (Chiang N, Serhan C N, Dahlen, S, Drazen J M, Hay D W P, Rovati E, Shimizu T, Yokomizo T, Brink, C. The lipoxin receptor ALX: Potent ligand-specific and stereoselective actions in vivo. Pharmacological Reviews 2006; 58: 463-519). FPR2 is an exceptionally promiscuous receptor that responds to a large array of exogenous and endogenous ligands, including serum amyloid A (SAA), chemokine variant sCKβ8-1, the neuroprotective peptide humanin, anti-inflammatory eicosanoid lipoxin A4 (LXA4) and glucocorticoid-modulated protein annexin A1 (Chiang N, Serhan C N, Dahlen, S, Drazen J M, Hay D W P, Rovati E, Shimizu T, Yokomizo T, Brink, C. The lipoxin receptor ALX: Potent ligand-specific and stereoselective actions in vivo. Pharmacological Reviews 2006; 58: 463-519). FPR2 transduces anti-inflammatory effects of LXA4 in many systems, and has been shown to play a key role in the resolution of inflammation (Dufton N, Perretti M. Therapeutic anti-inflammatory potential of formyl peptide receptor agonists. Pharmacology & Therapeutics 2010; 127: 175-188). FPR2 knockout mice show exaggerated inflammation in disease conditions as expected by the biological role of the receptor (Dufton N, Hannon R, Brancaleone V, Dalli J, Patel HB, Gray M, D'Aquisto F, Buckingham J C, Perretti M, Flower R J. Anti-inflammatory role of the murine formyl-peptide receptor 2: Ligand-specific effects on leukocyte responses and experimental inflammation. Journal of Immunology 2010; 184: 2611-2619).

Activation of FPR2 by lipoxin A4 or its analogs and by Annexin I protein has been shown to result in anti-inflammatory activity by promoting active resolution of inflammation which involves inhibition of polymorphonuclear neutrophils (PMNs) and eosinophils migration and also stimulate monocyte migration enabling clearance of apoptotic cells from the site of inflammation in a nonphlogistic manner (Maderna P, Cotten DC, Toivonen T, Dufton N, Dalli J, Perretti M, Godson C. FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis. FASEB 2010; 24: 4240-4249; Reville K, Cream J K, Vivers S, Dransfield I, Godson C. Lipoxin A4 redistributes Myosin IIA and Cdc42 in macrophages: Implications for phagocytosis of apoptotic leukocytes. Journal of Immunology 2006; 176: 1878-1888). In addition, FPR2 has been shown to inhibit NK cytotoxicity and promote activation of T cells which further contributes to down regulation of tissue damaging inflammatory signals. FPR2/LXA4 interaction has been shown to be beneficial in experimental models of ischemia reperfusion, angiogenesis, ocular inflammation such as endotoxin-induced uveitis, and corneal wound healing (Serhan C. Resolution phase of inflammation: Novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annual reviews of Immunology 2007; 25: 101-137; Medeiros R, Rodrigues G B, Figueiredo C P, Rodrigues E B, Grumman A Jr, Menezes-de-Lima O Jr, Passos G F, Calixto J B. Molecular mechanisms of topical anti-inflammatory effects of lipoxin A(4) in endotoxin-induced uveitis. Molecular Pharmacology 2008; 74: 154-161; Gronert K, Maheshwari N, Khan N, Hassan I R, Dunn M, Schwartzmann M L. A role for the mouse 12/15-lipoxygenase pathways in promoting epithelial wound healing and host defense. Journal of Biological Chemistry 2005; 280: 15267-15278; Leedom A, Sullivan A B, Dong B, Lau D, Gronert K. Endogenous LXA4 circuits are determinants of pathological angiogenesis in response to chronic injury. American Journal of Pathology 2010; 176: 74-84; Gronert K. Lipoxins in the eye and their role in wound healing. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2005; 73: 221-229). Pharmaceutical utility of lipoxin A4 and its analogs are hampered by inherent physicochemical properties of the natural poly-olefinic natural product. Therefore, small molecule anti-inflammatory agonists of FPR2 would have a wide variety of therapeutic benefit in inflammatory disorders especially in the eye. Targeting FPR2 selectively would also have benefits of reduced side effects as compared to more broad acting anti-inflammatories such as steroids or NSAIDs which have significant side effects of elevated IOP and delays in wound healing in the eye. FPR2 is also expressed in ocular tissues in the cornea and also the posterior of eye, in addition to the inflammatory cells that migrate into the ocular tissues. FPR2 thus represents an important novel pro-resolutionary molecular target for the development of new therapeutic agents in ocular diseases with excessive inflammatory responses.

BRIEF DESCRIPTION OF THE INVENTION

The invention pertains to the ability of FPR2 agonists to exhibit ocular anti-inflammatory activity with chemical stability and suitable for ocular delivery. These FPR2 compounds show good potency at the receptor, a subset of compounds is exemplified in the tables below, and importantly, the FPR2 compounds are active topically, and therefore could be administered in many forms, including but not limited to eye drops. These compounds may also be administered directly or through a local drug delivery device applied to ocular tissue, and via IV, intramuscularly, intrathecally, subcutaneously, orally, intravitreally or intraperitoneally. These compounds will be useful for the treatment of ocular inflammatory diseases including, but not limited to, uveitis, dry eye, keratitis, allergic eye disease, infectious keratitis, herpetic keratitis, corneal angiogenesis, lymphangiogenesis, uveitis, retinitis, and choroiditis such as acute multifocal placoid pigment epitheliopathy, Behcet's disease, post-surgical corneal wound healing, conditions caused by laser, conditions caused by photodynamic therapy, wet and dry age-related macular degeneration (ARMD), conditions affecting the posterior part of the eye, such as maculopathies and retinal degeneration including non-exudative age related macular degeneration, exudative age related macular degeneration, choroidal neovascularization, diabetic retinopathy (proliferative), retinopathy of prematurity (ROP), acute macular neuroretinopathy, central serous chorioretinopathy, cystoid macular edema, and diabetic macular edema; birdshot retinochoroidopathy, infectious (syphilis, lyme, tuberculosis, toxoplasmosis), intermediate uveitis (pars planitis), multifocal choroiditis, multiple evanescent white dot syndrome (mewds), ocular sarcoidosis, posterior scleritis, serpiginous choroiditis, subretinal fibrosis and uveitis syndrome, Vogt-Koyanagi and Harada syndrome; vascular diseases/exudative diseases such as retinal arterial occlusive disease, central retinal vein occlusion, cystoids macular edema, disseminated intravascular coagulopathy, branch retinal vein occlusion, hypertensive fundus changes, ocular ischemic syndrome, retinal arterial microaneurysms, Coat's disease, parafoveal telangiectasis, hemi-retinal vein occlusion, papillophlebitis, central retinal artery occlusion, branch retinal artery occlusion, carotid artery disease (CAD), frosted branch angiitis, sickle cell retinopathy and other hemoglobinopathies, angioid streaks, familial exudative vitreoretinopathy, and Eales disease; traumatic/surgical conditions such as sympathetic ophthalmia, uveitic retinal disease, retinal detachment, trauma, conditions caused by photodynamic therapy, photocoagulation, hypoperfusion during surgery, radiation retinopathy, and bone marrow transplant retinopathy; proliferative disorders such as proliferative vitreal retinopathy and epiretinal membranes, and proliferative diabetic retinopathy; infectious disorders such as ocular histoplasmosis, ocular toxocariasis, presumed ocular histoplasmosis syndrome (POHS), endophthalmitis, toxoplasmosis, retinal diseases associated with HIV infection, choroidal disease associate with HIV infection, uveitic disease associate with HIV infection, viral retinitis, acute retinal necrosis, progressive outer retinal necrosis, fungal retinal diseases, ocular syphilis, ocular tuberculosis, diffuse unilateral subacute neuroretinitis, and myiasis; genetic disorders such as retinitis pigmentosa, systemic disorders with associated retinal dystrophies, congenital stationary night blindness, cone dystrophies, Stargardt's disease and fundus flavimaculatus, Best's disease, pattern dystrophy of the retinal pigmented epithelium, X-linked retinoschisis, Sorsby's fundus dystrophy, benign concentric maculopathy, Bietti's crystalline dystrophy, and pseudoxanthoma elasticum; retinal tears/holes such as retinal detachment, macular hole, and giant retinal tear; tumors such as retinal disease associated with tumors, congenital hypertrophy of the retinal pigmented epithelium, posterior uveal melanoma, choroidal hemangioma, choroidal osteoma, choroidal metastasis, combined hamartoma of the retina and retinal pigmented epithelium, retinoblastoma, vasoproliferative tumors of the ocular fundus, retinal astrocytoma, and intraocular lymphoid tumors; and miscellaneous other diseases affecting the posterior part of the eye such as punctate inner choroidopathy, acute posterior multifocal placoid pigment epitheliopathy, myopic retinal degeneration, and acute retinal pigment epitheliitis, post-surgical corneal inflammation, blepharitis, MGD, glaucoma, branch vein occlusion, Best's vitelliform macular degeneration, retinitis pigmentosa, proliferative vitreoretinopathy (PVR), and any other degenerative diseases of either the photoreceptors or the retinal pigment epithelial (RPE).

In another aspect these compounds will be useful for the treatment of ocular inflammatory diseases associated with CNS disorders such as Alzheimer's disease, arthritis, sepsis, inflammatory bowel disease, cachexia, angina pectoris, rheumatoid arthritis and related inflammatory disorders, alopecia, systemic inflammatory diseases such as stroke, coronary artery disease, obstructive airway diseases, HIV-mediated retroviral infections, cardiovascular disorders including coronary artery disease, neuroinflammation, neurological disorders, pain and immunological disorders, asthma, allergic disorders, inflammation, systemic lupus erythematosus.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 FPR2 agonists show potent anti-inflammatory activity in endotoxin-induced uveitis model in rats.

FIG. 2 FPR2 agonists show potent anti-inflammatory activity in endotoxin-induced uveitis model in rats.

FIG. 3 shows accelerated healing and re-epithelialization in a rabbit model of corneal wound as exemplified by Compound 3, {[(2S,3S)-2-{[(4-bromophenyl)carbamoyl]amino}-3-methylpentanoyl]amino}acetic acid.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of FPR2. In another aspect, the invention provides the use of at least one agonist of FPR2 for the manufacture of a medicament for the treatment of an ocular inflammatory disease or condition mediated by FPR2 in a mammal.

In another aspect, the invention provides a method for treating ocular inflammatory diseases, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of FPR2 as disclosed in U.S. patent application Ser. No. 13/668,835, provided that the compounds have binding activity at the FPR2 receptor.

In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application Ser. No. 13/668,835 for the manufacture of a medicament for the treatment of an ocular disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.

In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application Ser. No. 13/668,835 for treating an ocular disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor

The compounds disclosed in U.S. patent application Ser. No. 13/668,835 are represented by Formula I:

wherein:

R¹ is sec-butyl, C₆₋₁₀ aryl, —CH₂—(C₆₋₁₀)aryl, —CH₂-heterocycle, C₄₋₈ cycloalkyl or C₃₋₈ cycloalkenyl or heterocycle;

R² is halogen or methyl;

R³ is halogen;

R⁴ is H, methyl or halogen;

R⁵ is OR⁶ or NH₂;

R⁶ is H or C₂₋₄ alkyl.

In another aspect, the invention provides a method for treating ocular inflammatory diseases, which comprises administering a pharmaceutical composition, comprising a therapeutically effective amount of at least one agonist of FPR2 as disclosed in U.S. patent application Ser. No. 13/523,579, provided that the compounds have binding activity at the FPR2 receptor.

In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application Ser. No. 13/523,579 for the manufacture of a medicament for the treatment of an ocular disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.

In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application Ser. No. 13/523,579 for treating an ocular disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.

The compounds disclosed in U.S. patent application Ser. No. 13/523,579 are represented by Formula II:

wherein:

a is 1 and b is 0;

a is 0 and b is 1;

a is 1 and b is 1;

R¹ is optionally substituted C₁₋₈ alkyl, optionally substituted C₃₋₈ cycloalkyl, optionally substituted heterocycle, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₃₋₈ cycloalkenyl, —NR¹¹R¹² or —OR¹³;

R² is optionally substituted C₁₋₈ alkyl or optionally substituted C₆₋₁₀ aryl;

R³ is hydrogen, optionally substituted C₁₋₈ alkyl, halogen, —COOR¹⁵, —OR¹³, —NR¹¹R¹², NO₂, optionally substituted heterocycle, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₆₋₁₀ aryl or optionally substituted C₃₋₈ cycloalkenyl;

R⁴ is hydrogen, optionally substituted C₁₋₈ alkyl, halogen, —COOR¹⁵, —OR¹³, —NR¹¹R¹², NO₂, optionally substituted heterocycle, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₆₋₁₀ aryl or optionally substituted C₃₋₈ cycloalkenyl;

R⁵ is halogen, —CF₃ or —S(O)_(n)R¹⁴;

n is 0, 1 or 2;

R⁶ is hydrogen, optionally substituted C₁₋₈ alkyl, halogen, —COOR¹⁵, —OR¹³, —NR¹¹R¹², NO₂, optionally substituted heterocycle, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₆₋₁₀ aryl or optionally substituted C₃₋₈ cycloalkenyl;

R⁷ is hydrogen, optionally substituted C₁₋₈ alkyl, halogen, —COOR¹⁵, —OR¹³, —NR¹¹R¹², NO₂, optionally substituted heterocycle, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₆₋₁₀ aryl or optionally substituted C₃₋₈ cycloalkenyl;

R⁸ is hydrogen, optionally substituted C₁₋₈ alkyl or optionally substituted C₆₋₁₀ aryl;

R⁹ is hydrogen, optionally substituted C₁₋₈ alkyl or optionally substituted C₆₋₁₀ aryl;

R¹⁰ is hydrogen, optionally substituted C₁₋₈ alkyl or optionally substituted C₆₋₁₀ aryl;

R^(9a) is hydrogen, optionally substituted C₁₋₈ alkyl or optionally substituted C₆₋₁₀ aryl;

R^(10a) is hydrogen, optionally substituted C₁₋₈ alkyl or optionally substituted C₆₋₁₀ aryl;

R¹¹ is hydrogen or optionally substituted C₁₋₈ alkyl;

R¹² is hydrogen or optionally substituted C₁₋₈ alkyl;

R¹³ is hydrogen or optionally substituted C₁₋₈ alkyl;

R¹⁴ is hydrogen, CF3 or optionally substituted C₁₋₈ alkyl;

R¹⁵ is hydrogen or optionally substituted C₁₋₈ alkyl.

In another aspect, the invention provides a method for treating ocular inflammatory diseases, which comprises administering a pharmaceutical composition, comprising a therapeutically effective amount of at least one agonist of FPR2 as disclosed in U.S. patent application Ser. No. 13/673,800, provided that the compounds have binding activity at the FPR2 receptor.

In another aspect, the invention provides the use of at least a compound as disclosed in U.S. patent application Ser. No. 13/673,800 for the manufacture of a medicament for the treatment of an ocular disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.

In another aspect, the invention provides the use of at least a compound as disclosed in U.S. patent application Ser. No. 13/673,800 for treating an ocular disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.

The compounds disclosed in U.S. patent application Ser. No. 13/673,800 are represented by Formula III:

wherein:

R¹ is halogen, hydrogen, optionally substituted C₁₋₈ alkyl, OR⁹, C(O)R¹⁰, NO₂, NR¹³R¹⁴, CN, SR¹⁵ or SO₂R¹⁶;

R² is halogen, optionally substituted C₁₋₈ alkyl, CF₃, OR⁹, C(O)R¹⁰, NO₂, NR¹³R¹⁴, CN, SR¹⁵ or SO₂R¹⁶;

R³ is hydrogen, optionally substituted C₁₋₈ alkyl, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₃₋₈ cycloalkenyl, optionally substituted C₆₋₁₀ aryl, optionally substituted heterocycle, or together with R⁵ forms a 10- or 11-membered polycyclic ring which is optionally substituted;

R⁴ is hydrogen, optionally substituted C₁₋₈ alkyl,

optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₃₋₈ cycloalkenyl, optionally substituted C₆₋₁₀ aryl, optionally substituted heterocycle, or together with R⁵ forms a spiro monocyclic or polycyclic, carbocyclic or heterocyclic, saturated or unsaturated 5 to 10 member ring which is optionally substituted;

R⁵ is hydrogen, optionally substituted C₁₋₈ alkyl, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₃₋₈ cycloalkenyl, optionally substituted C₆₋₁₀ aryl, optionally substituted heterocycle, or together with R⁴ forms a spiro monocyclic or polycyclic, carbocyclic or heterocyclic, saturated or unsaturated 5 to 10 member ring which is optionally substituted or together with R³ forms a 5 or 6 member ring which is optionally substituted;

R⁶ is halogen, hydrogen, optionally substituted C₁₋₈ alkyl, OR⁹, C(O)R¹⁰, NO₂, NR¹³R¹⁴, CN, SR¹⁵ or SO₂R¹⁶;

R⁷ is halogen, hydrogen, optionally substituted C₁₋₈ alkyl, OR⁹, C(O)R¹⁰, NO₂, NR¹³R¹⁴, CN, SR¹⁵ or SO₂R¹⁶;

R⁸ is halogen, hydrogen, optionally substituted C₁₋₈ alkyl, OR⁹, C(O)R¹⁰, NO₂, NR¹³R¹⁴, CN, SR¹⁵ or SO₂R¹⁶;

R⁹ is hydrogen, C(O)(C₁₋₈ alkyl) or optionally substituted C₁₋₈ alkyl;

R¹⁰ is hydrogen, optionally substituted C₁₋₈ alkyl, O(C₁₋₈ alkyl), NR¹¹R¹² or OH;

R¹¹ is hydrogen, optionally substituted C₆₋₁₀ aryl or optionally substituted C₁₋₈ alkyl;

R¹² is hydrogen, optionally substituted C₆₋₁₀ aryl or optionally substituted C₁₋₈ alkyl;

R¹³ is hydrogen, optionally substituted C₆₋₁₀ aryl or optionally substituted C₁₋₈ alkyl;

R¹⁴ is hydrogen, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₈ alkyl, C(O)(C₁₋₈ alkyl) or SO₂(C₁₋₈ alkyl);

R¹⁵ is hydrogen, optionally substituted C₁₋₈ alkyl or O(C₁₋₈ alkyl);

R¹⁶ is OH, O(C₁₋₈ alkyl), (C₁₋₈ alkyl) or NR¹¹R¹²;

R¹⁷ is hydrogen, optionally substituted C₆₋₁₀ aryl or optionally substituted C₁₋₈ alkyl;

R¹⁸ is hydrogen, C(O)(C₁₋₈ alkyl), optionally substituted C₆₋₁₀ aryl, or optionally substituted C₁₋₈ alkyl;

R¹⁹ is hydrogen, C(O)(C₁₋₈ alkyl), optionally substituted C₆₋₁₀ aryl or optionally substituted C₁₋₈ alkyl;

R²⁰ is hydrogen, optionally substituted C₆₋₁₀ aryl or optionally substituted C₁₋₈ alkyl;

R²¹ is hydrogen, optionally substituted C₆₋₁₀ aryl or optionally substituted C₁₋₈ alkyl;

n is 1, 2, 3, 4, or 5;

m is 1, 2, 3, 4, or 5.

In another aspect, the invention provides a method for treating ocular inflammatory diseases, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of FPR2 as disclosed in U.S. patent application Ser. No. 13/765,527, provided that the compounds have binding activity at the FPR2 receptor.

In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application Ser. No. 13/765,527 for the manufacture of a medicament for the treatment of an ocular disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.

In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application Ser. No. 13/765,527 for treating an ocular disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.

The compounds disclosed in U.S. patent application Ser. No. 13/765,527 are represented by Formula IV:

wherein:

R¹ is hydrogen, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted C₃₋₈ cycloalkyl, substituted or unsubstituted C₃₋₈ cycloalkenyl, substituted or unsubstituted heterocycle or substituted or unsubstituted C₆₋₁₀ aryl, or together with R² can form an optionally substituted cyclobutyl;

R² is isopropyl or together with R³ can form a substituted or unsubstituted 3 to 6 member ring heterocycle or together with R¹ can form an optionally substituted cyclobutyl, cyclopropyl; and

R³ is hydrogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted C₃₋₈ cycloalkyl, substituted or unsubstituted C₃₋₈ cycloalkenyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C₆₋₁₀ aryl or together with R² can form a substituted or unsubstituted 3 to 6 member ring heterocycle.

In another aspect, the invention provides a method for treating ocular inflammatory diseases, which comprises administering a therapeutically effective amount of a pharmaceutical composition, comprising at least one agonist of FPR2 as disclosed in U.S. patent application Ser. No. 13/409,228, provided that the compounds have binding activity at the FPR2 receptor.

In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application Ser. No. 13/409,228 for the manufacture of a medicament for the treatment of an ocular disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.

In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application Ser. No. 13/409,228 for treating an ocular disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.

The compounds disclosed in U.S. patent application Ser. No. 13/409,228 are represented by Formula V:

wherein:

“

” is a single bond or a double bond;

“

” is a single bond or a double bond;

R¹ is H, halogen, —S(O)R¹⁰, —S(O)₂R¹¹, nitro, cyano, —OC₁₋₆ alkyl, —SC₁₋₆ alkyl, —C₁₋₆ alkyl, —C₂₋₆ alkenyl, —C₂₋₆ alkynyl, C(O)R¹², NR¹³R¹⁴, C₃₋₈ cycloalkyl, C₃₋₈ cycloalkenyl or hydroxyl;

R² is H, halogen, —S(O)R¹⁰, —S(O)₂R¹¹, nitro, cyano, —OC₁₋₆ alkyl, —SC₁₋₆ alkyl, —C₁₋₆ alkyl, —C₂₋₆ alkenyl, —C₂₋₆ alkynyl, C(O)R¹², NR¹³R¹⁴, C₃₋₈ cycloalkyl, C₃₋₈ cycloalkenyl or hydroxyl;

R³ is H, halogen, —S(O)R¹⁰, —S(O)₂R¹¹, nitro, cyano, —OC₁₋₆ alkyl, —SC₁₋₆ alkyl, —C₁₋₆ alkyl, —C₂₋₆ alkenyl, —C₂₋₆ alkynyl, C(O)R¹², NR¹³R¹⁴, C₃₋₈ cycloalkyl, C₃₋₈ cycloalkenyl, C₆₋₁₀ aryl or hydroxyl;

R⁴ is H or C(O)R¹²;

R⁵ is H, —OC₁₋₆ alkyl, —SC₁₋₆ alkyl, —C₁₋₆ alkyl, —C₂₋₆ alkenyl or —C₂₋₆ alkynyl;

R⁶ is H, —OC₁₋₆ alkyl, —SC₁₋₆ alkyl, —C₁₋₆ alkyl, —C₂₋₆ alkenyl or —C₂₋₆ alkynyl;

Y is O or S;

X is O, NR, or CH₂;

R^(a) is C₆₋₁₀ aryl,

heteroaryl, C₃₋₈ cycloalkyl, C₃₋₈ cycloalkenyl or H;

R^(b) is halogen;

c is 0, 1 or 2;

R⁷ is H, halogen, —S(O)R¹⁰, —S(O)₂R¹¹, nitro, hydroxyl, cyano, —OC₁₋₆ alkyl, —SC₁₋₆alkyl, —C₁₋₆ alkyl, —C₂₋₆ alkenyl, —C₂₋₆ alkynyl, C(O)R¹², NR¹³R¹⁴, C₃₋₈ cycloalkenyl or C₃₋₈ cycloalkyl;

R⁸ is H, halogen, —S(O)R¹⁰, —S(O)₂R¹¹, cyano, —OC₁₋₆ alkyl, —SC₁₋₆ alkyl, —C₁₋₆ alkyl, —C₂₋₆ alkenyl, —C₂₋₆ alkynyl, C(O)R¹², NR¹³R¹⁴, C₃₋₈ cycloalkenyl or C₃₋₈ cycloalkyl;

R⁹ is H, —S(O)₂R¹¹, —OC₁₋₆ alkyl, —SC₁₋₆ alkyl, —C₁₋₆ alkyl, —C₂₋₆ alkenyl, —C₂₋₆ alkynyl, C(O)R¹², C₃₋₈ cycloalkenyl or C₃₋₈ cycloalkyl;

R¹⁰ is —C₁₋₆ alkyl, C₃₋₈ cycloalkyl, or C₃₋₈ cycloalkenyl;

R¹¹ is H, hydroxyl, —C₁₋₆ alkyl, C₃₋₈ cycloalkyl or C₃₋₈ cycloalkenyl;

R¹² is H, hydroxyl, —C₁₋₆ alkyl, C₃₋₈ cycloalkyl, C₃₋₈ cycloalkenyl, NR¹³R¹⁴ or —OC₁₋₆ alkyl;

R¹³ is H, —C₁₋₆ alkyl, C₃₋₈ cycloalkyl, C₃₋₈ cycloalkenyl SO₂R¹¹ or C(O)R¹⁵;

R¹⁴ is H, —C₁₋₆ alkyl, C₃₋₈ cycloalkenyl, aryl, heterocycle or C₃₋₈ cycloalkyl;

R¹⁵ is H, —C₁₋₆ alkyl, C₃₋₈ cycloalkenyl or C₃₋₈ cycloalkyl; and

R is H, —C₁₋₆ alkyl, C₃₋₈ cycloalkenyl or C₃₋₈ cycloalkyl;

with the provisos:

when “

” is a double bond then R⁵ is void; and

when “

” is a double bond R⁶ is void.

In another aspect, the invention provides a method for treating ocular inflammatory diseases, which comprises administering a pharmaceutical composition, comprising a therapeutically effective amount of at least one agonist of FPR2 as disclosed in U.S. patent application Ser. No. 13/370,472, provided that the compounds have binding activity at the FPR2 receptor.

In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application Ser. No. 13/370,472 for the manufacture of a medicament for the treatment of an ocular disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.

In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application Ser. No. 13/370,472 for treating an ocular disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.

The compounds as disclosed in U.S. patent application Ser. No. 13/370,472 are represented by Formula VI:

wherein:

A is C₆₋₁₀ aryl, heterocycle, C₃₋₈ cycloalkyl or C₃₋₈ cycloalkenyl;

R¹⁷ is C₁₋₆ alkyl or

B is C₆₋₁₀ aryl, heterocycle, C₃₋₈ cycloalkyl or C₃₋₈ cycloalkenyl;

R¹ is H, halogen, —S(O)R¹⁵, —S(O)₂R¹¹, nitro, cyano, —OC₁₋₆ alkyl, —SC₁₋₆ alkyl, —C₁₋₆ alkyl, —C₂₋₆ alkenyl, —C₂₋₆ alkynyl, C(O)R¹², NR¹³R¹⁴, C₃₋₈ cycloalkyl or hydroxyl;

R² is H, halogen, —S(O)R¹⁵, —S(O)₂R¹¹, nitro, cyano, —OC₁₋₆ alkyl, —SC₁₋₆ alkyl, —C₁₋₆ alkyl, —C₂₋₆ alkenyl, —C₂₋₆ alkynyl, C(O)R¹², NR¹³R¹⁴, C₃₋₈ cycloalkyl or hydroxyl;

R³ is H, C₁₋₆ alkyl or C₃₋₈ cycloalkyl;

R⁴ is H, C₁₋₆ alkyl or C₃₋₈ cycloalkyl;

R^(5a) is H, halogen, —S(O)R¹⁵, —S(O)₂R¹¹, nitro, cyano, —OC₁₋₆ alkyl, —SC₁₋₆ alkyl, —C₁₋₆ alkyl, —C₂₋₆ alkenyl, —C₂₋₆ alkynyl, C(O)R¹², NR¹³R¹⁴, C₃₋₈ cycloalkyl or hydroxyl;

R^(5b) is H, halogen, —S(O)R¹⁵, —S(O)₂R¹¹, nitro, cyano, —OC₁₋₆ alkyl, —SC₁₋₆ alkyl, —C₁₋₆ alkyl, —C₂₋₆ alkenyl, —C₂₋₆ alkynyl, C(O)R¹², NR¹³R¹⁴, C₃₋₈ cycloalkyl or hydroxyl;

R^(5c) is H, halogen, —S(O)R¹⁵, —S(O)₂R¹¹, nitro, cyano, —OC₁₋₆ alkyl, —SC₁₋₆ alkyl, —C₁₋₆ alkyl, 'C₂₋₆ alkenyl, —C₂₋₆ alkynyl, C(O)R¹², NR¹³R¹⁴, C₃₋₈ cycloalkyl or hydroxyl;

R^(5d) is H, halogen, —S(O)R¹⁵, —S(O)₂R¹¹, nitro, cyano, —OC₁₋₆ alkyl, —SC₁₋₆ alkyl, —C₁₋₆ alkyl, —C₂₋₆ alkenyl, —C₂₋₆ alkynyl, C(O)R¹², NR¹³R¹⁴, C₃₋₈ cycloalkyl or hydroxyl;

R⁶ is H, —S(O)₂R¹¹, —C₁₋₆ alkyl, —(CH₂)_(n)NR¹³R¹⁴, —(CH₂)_(m) heterocycle, C(O)R¹², NR¹³R¹⁴, C₃₋₈ cycloalkyl, C₆₋₁₀ aryl, or heterocycle;

R⁷ is H, halogen, —S(O)R¹⁵, —S(O)₂R¹¹, nitro, cyano, —OC₁₋₆ alkyl, —SC₁₋₆ alkyl, —C₁₋₆ alkyl, —C₂₋₆ alkenyl, —C₂₋₆ alkynyl, C(O)R¹², NR¹³R¹⁴, C₃₋₈ cycloalkyl or hydroxyl;

R⁸ is H, halogen, —S(O)R¹⁵, —S(O)₂R¹¹, nitro, cyano, —OC₁₋₆ alkyl, —SC₁₋₆ alkyl, —C₁₋₆ alkyl, —C₂₋₆ alkenyl, —C₂₋₆ alkynyl, C(O)R¹², NR¹³R¹⁴, C₃₋₈ cycloalkyl or hydroxyl;

R⁹ is H, halogen, —S(O)R¹⁵, —S(O)₂R¹¹, nitro, cyano, —OC₁₋₆ alkyl, —SC₁₋₆ alkyl, —C₁₋₆ alkyl, —C₂₋₆ alkenyl, —C₂₋₆ alkynyl, C(O)R¹², NR¹³R¹⁴, C₃₋₈ cycloalkyl or hydroxyl;

R¹⁰ is H, halogen, —S(O)R¹⁵, —S(O)₂R¹¹, nitro, cyano, —OC₁₋₆ alkyl, —SC₁₋₆ alkyl, —C₁₋₆ alkyl, —C₂₋₆ alkenyl, —C₂₋₆ alkynyl, C(O)R¹², NR¹³R¹⁴, C₃₋₈ cycloalkyl or hydroxyl;

X is O or S;

Y is O or S;

R¹¹ is H, hydroxyl, —C₁₋₆ alkyl, C₃₋₈ cycloalkyl or NR¹³R¹⁴;

R¹² is H, hydroxyl, —C₁₋₆ alkyl, hydroxyl, C₃₋₈ cycloalkyl, NR¹³R¹⁴ or —OC₁₋₆ alkyl;

R¹³ is H, —C₁₋₆ alkyl, C₃₋₈ cycloalkyl, SO₂R¹¹ or C(O)R¹⁶;

R¹⁴ is H, —C₁₋₆ alkyl or C₃₋₈ cycloalkyl;

R¹⁵ is —C₁₋₆ alkyl, or C₃₋₈ cycloalkyl;

R¹⁶ is H, —C₁₋₆ alkyl or C₃₋₈ cycloalkyl;

n is 1-4; and

m is 1-4.

In another aspect, the invention provides a method for treating ocular inflammatory diseases, which comprises administering a pharmaceutical composition, comprising a therapeutically effective amount of at least one agonist of FPR2 as disclosed in U.S. patent application Ser. No. 13/863,934, provided that the compounds have binding activity at the FPR2 receptor.

In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application Ser. No. 13/863,934 for the manufacture of a medicament for the treatment of an ocular disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.

In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application Ser. No. 13/863,934 for treating an ocular disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.

The compounds as disclosed in U.S. patent application Ser. No. 13/863,934 are represented by Formula VII:

wherein:

n is 0 or 1;

R¹ is hydrogen, substituted or unsubstituted C₁₋₈ alkyl, halogen, —NR⁸R⁹, —NC(O)R²⁰, —OR¹⁰, —OC(O)R²¹, —SR¹¹, —C(O)R¹², CN or NO₂;

R² is hydrogen, substituted or unsubstituted C₁₋₈ alkyl, halogen, —NR⁸R⁹, —NC(O)R²⁰, —OR¹⁰, —OC(O)R²¹, —SR¹¹, —C(O)R¹², CN or NO₂;

R³ is hydrogen, substituted or unsubstituted C₁₋₈ alkyl, halogen, —NR⁸R⁹, —NC(O)R²⁰, —OR¹⁰, —OC(O)R²¹, —SR¹¹, —C(O)R¹², CN, NO₂, CF₃, S(O)R¹⁵ or S(O)₂R¹⁶;

R⁴ is hydrogen, substituted or unsubstituted C₁₋₈ alkyl, halogen, —NR⁸R⁹, —NC(O)R²⁰, —OR¹⁰, —OC(O)R²¹, —SR¹¹, —C(O)R¹², CN or NO₂;

R⁵ is hydrogen, substituted or unsubstituted C₁₋₈ alkyl, halogen, —NR⁸R⁹, -NC(O)R²⁰, —OR¹⁰, —OC(O)R²¹, SR¹¹, —C(O)R¹², CN or NO₂;

R⁶ is hydrogen, substituted or unsubstituted C₁₋₈ alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C₃₋₈ cycloalkyl, substituted or unsubstituted C₆₋₁₀ aryl, substituted or unsubstituted C₃₋₈ cycloalkenyl or —CH₂R¹⁹;

R⁷ is substituted or unsubstituted heterocycle, —SR¹¹, —NR⁸R⁹, —N(H)C(O)N(H)S(O)₂R¹⁹, —BR¹³R¹⁴, —S(O)R¹⁵, —C(O)N(H)(CN), —C(O)N(H)S(O)₂R¹⁹, —S(O)(N)(PO₃H₂)—, —S(O)₂R¹⁶ or —P(O)R¹⁷R¹⁸;

R⁸ is hydrogen, substituted or unsubstituted C₁₋₈ alkyl, substituted or unsubstituted C₃₋₈ cycloalkyl, substituted or unsubstituted heterocycle, or substituted or unsubstituted C₆₋₁₀ aryl;

R⁹ is hydrogen, substituted or unsubstituted C₁₋₈ alkyl, substituted or unsubstituted C₃₋₈ cycloalkyl, substituted or unsubstituted heterocycle, or substituted or unsubstituted C₆₋₁₀ aryl;

R¹⁰ is hydrogen or substituted or unsubstituted C₁₋₈ alkyl;

R¹¹ is hydrogen , substituted or unsubstituted C₁₋₈ alkyl or —CF₃;

R¹² is hydrogen, substituted or unsubstituted C₁₋₈ alkyl, hydroxyl, —OR²⁴ or —NR⁸R⁹;

R¹³ is —OR²²;

R¹⁴ is —OR²³;

R¹⁵ is substituted or unsubstituted C₁₋₈ alkyl;

R¹⁶ is substituted or unsubstituted C₁₋₈ alkyl, —NR⁸R⁹, —NHS(O)₂R¹⁹ or hydroxyl;

R¹⁷ is OR¹⁰ or NR⁸R⁹;

R¹⁸ is OR¹⁰ or NR⁸R⁹;

R¹⁹ is substituted or unsubstituted heterocycle, substituted or unsubstituted C₃₋₈ cycloalkyl, substituted or unsubstituted C₆₋₁₀ aryl or substituted or unsubstituted C₃₋₈ cycloalkenyl;

R²⁰ is hydrogen, substituted or unsubstituted C₁₋₈ alkyl, substituted or unsubstituted C₃₋₈ cycloalkyl, substituted or unsubstituted heterocycle, or substituted or unsubstituted C₆₋₁₀ aryl;

R²¹ is hydrogen, substituted or unsubstituted C₁₋₈ alkyl, substituted or unsubstituted C₃₋₈ cycloalkyl, substituted or unsubstituted heterocycle, or substituted or unsubstituted C₆₋₁₀ aryl;

R²² is hydrogen, substituted or unsubstituted C₁₋₈ alkyl, or together with R²³ can form a cycle;

R²³ is hydrogen, substituted or unsubstituted C₁₋₈ alkyl, or together with R²² can form a cycle;

R²⁴ is hydrogen, substituted or unsubstituted C₁₋₈ alkyl, substituted or unsubstituted C₃₋₈ cycloalkyl, substituted or unsubstituted heterocycle, or substituted or unsubstituted C₆₋₁₀ aryl.

The term “alkyl”, as used herein, refers to saturated, monovalent or divalent hydrocarbon moieties having linear or branched moieties or combinations thereof and containing 1 to 8 carbon atoms. One methylene (—CH₂—) group, of the alkyl group can be replaced by oxygen, sulfur, sulfoxide, nitrogen, carbonyl, carboxyl, sulfonyl, sulfate, sulfonate, amide, sulfonamide, by a divalent C₃₋₈ cycloalkyl, by a divalent heterocycle, or by a divalent aryl group. Alkyl groups can have one or more chiral centers. Alkyl groups can be independently substituted by halogen atoms, hydroxyl groups, cycloalkyl groups, amino groups, heterocyclic groups, aryl groups, carboxylic acid groups, phosphonic acid groups, sulphonic acid groups, phosphoric acid groups, nitro groups, amide groups, sulfonamide groups.

The term “cycloalkyl”, as used herein, refers to a monovalent or divalent group of 3 to 8 carbon atoms derived from a saturated cyclic hydrocarbon. Cycloalkyl groups can be monocyclic or polycyclic. Cycloalkyl can be independently substituted by halogen atoms, sulfonyl C₁₋₈ alkyl groups, sulfoxide C₁₋₈ alkyl groups, sulfonamide groups, nitro groups, cyano groups, —OC₁₋₈ alkyl groups, —SC₁₋₈ alkyl groups, —C₁₋₈ alkyl groups, —C₂₋₆ alkenyl groups, —C₂₋₆ alkynyl groups, ketone groups, alkylamino groups, amino groups, aryl groups, C₃₋₈ cycloalkyl groups or hydroxyl groups.

The term “cycloalkenyl”, as used herein, refers to a monovalent or divalent group of 3 to 8 carbon atoms derived from a saturated cycloalkyl having at least one double bond. Cycloalkenyl groups can be monocyclic or polycyclic. Cycloalkenyl groups can be independently substituted by halogen atoms, sulfonyl groups, sulfoxide groups, nitro groups, cyano groups, —OC₁₋₆ alkyl groups, —SC₁₋₆ alkyl groups, —C₁₋₆ alkyl groups, —C₂₋₆ alkenyl groups, —C₂₋₆ alkynyl groups, ketone groups, alkylamino groups, amino groups, aryl groups, C₃₋₈ cycloalkyl groups or hydroxyl groups.

The term “halogen”, as used herein, refers to an atom of chlorine, bromine, fluorine, iodine.

The term “alkenyl”, as used herein, refers to a monovalent or divalent hydrocarbon radical having 2 to 6 carbon atoms, derived from a saturated alkyl, having at least one double bond. One methylene (—CH₂—) group, of the alkenyl can be replaced by oxygen, sulfur, sulfoxide, nitrogen, carbonyl, carboxyl, sulfonyl, sulfate, sulfonate, amide, sulfonamide, by a divalent C₃₋₈ cycloalkyl, by a divalent heterocycle, or by a divalent aryl group. C₂₋₆ alkenyl can be in the E or Z configuration. Alkenyl groups can be substituted by alkyl groups, as defined above or by halogen atoms.

The term “alkynyl”, as used herein, refers to a monovalent or divalent hydrocarbon radical having 2 to 6 carbon atoms, derived from a saturated alkyl, having at least one triple bond. One methylene (—CH₂—) group, of the alkynyl can be replaced by oxygen, sulfur, sulfoxide, nitrogen, carbonyl, carboxyl, sulfonyl, sulfate, sulfonate, amide, sulfonamide, by a divalent C₃₋₈ cycloalkyl, by a divalent heterocycle, or by a divalent aryl group. Alkynyl groups can be substituted by alkyl groups, as defined above, or by halogen atoms.

The term “heterocycle” as used herein, refers to a 3 to 10 membered ring, which can be aromatic or non-aromatic, saturated or unsaturated, containing at least one heteroatom selected form oxygen, nitrogen, sulfur, or combinations of at least two thereof, interrupting the carbocyclic ring structure. The heterocyclic ring can be interrupted by a C═O; the S and N heteroatoms can be oxidized. Heterocycles can be monocyclic or polycyclic. Heterocyclic ring moieties can be substituted by halogen atoms, sulfonyl groups, sulfoxide groups, nitro groups, cyano groups, —OC₁₋₆ alkyl groups, —SC₁₋₆ alkyl groups, —C₁₋₈ alkyl groups, —C₂₋₆ alkenyl groups, —C₂₋₆ alkynyl groups, ketone groups, alkylamino groups, amino groups, aryl groups, C₃₋₈ cycloalkyl groups or hydroxyl groups.

The term “aryl” as used herein, refers to an organic moiety derived from an aromatic hydrocarbon consisting of a ring containing 6 to 10 carbon atoms, by removal of one hydrogen atom. Aryl can be substituted by halogen atoms, sulfonyl C₁₋₆ alkyl groups, sulfoxide C₁₋₆ alkyl groups, sulfonamide groups, carboxylic acid groups, C₁₋₆ alkyl carboxylates (ester) groups, amide groups, nitro groups, cyano groups, —OC₁₋₆ alkyl groups, —SC₁₋₆ alkyl groups, —C₁₋₆ alkyl groups, —C₂₋₆ alkenyl groups, —C₂₋₆ alkynyl groups, ketone groups, aldehydes, alkylamino groups, amino groups, aryl groups, C₃₋₈ cycloalkyl groups or hydroxyl groups. Aryls can be monocyclic or polycyclic.

The term “hydroxyl” as used herein, represents a group of formula “—OH”.

The term “carbonyl” as used herein, represents a group of formula “—C(O)—”.

The term “ketone” as used herein, represents an organic compound having a carbonyl group linked to a carbon atom such as —(CO)R^(x) wherein R^(x) can be alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle as defined above.

The term “amine” as used herein, represents a group of formula “—NR^(x)R^(y)”, wherein R^(x) and R^(y) can be the same or independently H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle as defined above.

The term “carboxyl” as used herein, represents a group of formula “—C(O)O—”.

The term “sulfonyl” as used herein, represents a group of formula “—SO₂—”.

The term “sulfate” as used herein, represents a group of formula “—O—S(O)₂—O—”.

The term “sulfonate” as used herein, represents a group of the formula “—S(O)₂—O—”.

The term “carboxylic acid” as used herein, represents a group of formula “—C(O)OH”.

The term “nitro” as used herein, represents a group of formula “—NO₂”.

The term “cyano” as used herein, represents a group of formula “—CN”.

The term “amide” as used herein, represents a group of formula “—C(O)NR^(x)R^(y)” wherein R^(x) and R^(y) can be the same or independently H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle as defined above.

The term “sulfonamide” as used herein, represents a group of formula “—S(O)₂NR^(x)R^(y)” wherein R^(x) and R^(y) can be the same or independently H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle as defined above.

The term “sulfoxide” as used herein, represents a group of formula “—S(O)—”.

The term “phosphonic acid” as used herein, represents a group of formula “—P(O)(OH)₂”.

The term “phosphoric acid” as used herein, represents a group of formula “—OP(O)(OH)₂”.

The term “sulphonic acid” as used herein, represents a group of formula “—S(O)₂OH”.

The formula “H”, as used herein, represents a hydrogen atom.

The formula “O”, as used herein, represents an oxygen atom.

The formula “N”, as used herein, represents a nitrogen atom.

The formula “S”, as used herein, represents a sulfur atom.

In another aspect, agonists of FPR2 are compounds selected from Table 1:

TABLE 1 FPR2 Ga16-CHO EC₅₀ Structure IUPAC name (efficacy)

2-({[(4- chlorophenyl)amino]carbonyl}amino)-3- phenylpropanoic acid    110 nM (1.0)

(2S)-2-({[(4- methoxyphenyl)amino]carbonyl}amino)-3- phenylpropanoic acid    1754 nM (1.0)

(2S)-3-phenyl-2-[({[4- (trifluoromethyl)phenyl]amino}carbonyl) amino]propanoic acid    120 nM (0.97)

(2S)-2-({[(3,4- dichlorophenyl)amino]carbonyl}amino)-3- phenylpropanoic acid     10 □M (0.57)

(2S)-2-({[(4- nitrophenyl)amino]carbonyl}amino)-3- phenylpropanoic acid    574 nM (0.82)

3-phenyl-2-[({[4- (trifluoromethoxy)phenyl]amino}carbonyl) amino]propanoic acid    1572 nM (0.79)

2-({[(3,4- dimethoxyphenyl)amino]carbonyl}amino)- 3-phenylpropanoic acid    2793 nM (0.72)

methyl 2-({[(4- iodophenyl)amino]carbonyl}amino)-3- phenylpropanoate     14.3 nM (1.0)

(2S)-2-({[(4- bromophenyl)amino]carbonyl}amino)-3- phenylpropanoic acid     31 nM (1.0)

(2R)-2-({[(4- bromophenyl)amino]carbonyl}amino)-3- phenylpropanoic acid    1819 nM (0.99)

3-phenyl-2-{[(pyridin-3- ylamino)carbonyl]amino}propanoic acid >10000 nM

(2S,3S)-2-({[(4- bromophenyl)amino]carbonyl}amino)-3- methylpentanoic acid     4.1 nM (0.89)

(2S)-({[(4- bromophenyl)amino]carbonyl}amino) (phenyl)acetic acid     25.8 nM (0.94)

2-({[(4- bromophenyl)amino]carbonyl}amino)-3- (1H-indol-3-yl)propanoic acid     67.0 nM (0.89)

(2S)-2-({[(4- bromophenyl)amino]carbonyl}amino)-3- methylbutanoic acid     72 nM (0.91)

(2S)-2-({[(4-bromo-2- fluorophenyl)amino]carbonyl}amino)-3- methylbutanoic acid    152 nM (0.91)

US 2005/0137230 A1 and U.S. Pat. No. 7,820,673 disclose inhibitors of coagulation Factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and/or the treatment of tumors. 2-({[(4-chlorophenyl)amino]carbonyl}amino)-3-phenylpropanoic acid, (2S)-2-({[(4-methoxyphenyl)amino]carbonyl}amino)-3-phenylpropanoic acid, (2S)-3-phenyl-2-[({[4-(trifluoromethyl)phenyl]amino}carbonyl)amino]propanoic acid, methyl 2-({[(4-iodophenyl)amino]carbonyl}amino)-3-phenylpropanoate, (2S)-2-({[(4-bromophenyl)amino]carbonyl}amino)-3-phenylpropanoic acid, (2R)-2-({[(4-bromophenyl)amino]carbonyl}amino)-3-phenylpropanoic acid, are intermediates in the synthesis of urea derivatives as activated blood coagulation factor X (FXa) inhibitors.

JP 63232846 discloses the resolution of N-(p-bromophenylcarbamyl) derivatives ((2S)-2-({[(4-bromophenyl)amino]carbonyl}amino)-3-phenylpropanoic acid, (2S ,3S)-2-({[(4-bromophenyl)amino]carbonyl}amino)-3-methylpentanoic acid, 2-({[(4-bromophenyl)amino]carbonyl}amino)-3-(1H-indol-3-yl)propanoic acid, (2S)-2-({[(4-bromophenyl)amino]carbonyl}amino)-3-methylbutanoic acid) on HPLC column with novel chromatographic chiral stationary phases.

Journal of Chromatography (1987), 404(1), 117-22 and Chromatographia (1987), 23(10), 727-30 describe the resolution of p-Bromophenylcarbamyl derivatives of enantiomeric protein amino acids ((2R)-2-({[(4-bromophenyl)amino]carbonyl}amino)-3-phenylpropanoic acid, (2S)-2-({[(4-bromophenyl)amino]carbonyl}amino)-3-phenylpropanoic acid), on novel chiral stationary phase by elution with an aqueous mobile phase.

Biochimica et Biophysica Acta, Nucleic Acids and Protein Synthesis (1972), 272(4), 667-71 describes compound (2S)-2-({[(4-nitrophenyl)amino]carbonyl}amino)-3-phenylpropanoic acid) in poly(uridylic acid)-dependent binding of para nitrophenyl-carbamyl-phenylalanyl tRNA.

In another aspect, agonists of FPR2 are compounds selected from Table 2:

TABLE 2 FPR2 Ga16-CHO EC₅₀ Structure IUPAC name (efficacy)

1-(4-chlorophenyl)-3-(2,4-dioxo-1,3- diazaspiro[4,5]decan-3-yl)urea  49 nM (0.98)

1-(4-chlorophenyl)-3-(4-ethyl-4- methyl-2,5-dioxoimidazolidin-1- yl)urea 157 nM (0.96)

1-[4-methyl-2,5-dioxo-4-(2- phenylethyl)imidazolidin-1-yl]-3- phenylurea 223 nM (1.0)

1-(8-methyl-2,4-dioxo-1,3- diazaspiro[4,5]decan-3-yl)-3-(p- tolyl)urea 363 nM (0.91)

1-(2-fluorophenyl)-3-[4-methyl-2,5- dioxo-4-(2- phenylethyl)imidazolidin-1-yl]urea 258 nM (0.94)

Compounds of Table 2 are available from Chemical Libraries such as Aurora Fine Chemicals.

In another aspect, agonists of FPR2 are compounds selected from Table 3:

TABLE 3 FPR2 Ga16-CHO EC₅₀ Structure IUPAC name (efficacy)

N-(4-bromophenyl)-2-(4,4-dimethyl- 2,5-dioxoimidazolidin-1-yl)acetamide  719 nM (0.94)

N-(4-bromophenyl)-2-(4,4-diethyl-2,5- dioxoimidazolidin-1-yl)acetamide  96 nM (0.98)

N-(4-bromophenyl)-2-(2,4-dioxo-1,3- diazaspiro[4.5]dec-3-yl)acetamide  738 nM (0.89)

N-(4-bromophenyl)-2-(2,4-dioxo-1,3- diazaspiro[4.4]non-3-yl)acetamide  322 nM (0.96)

N-(4-bromophenyl)-2-(2,5-dioxo-4,4- dipropylimidazolidin-1-yl)acetamide  645 nM (0.98)

N-(4-bromophenyl)-2-(4-ethyl-2,5- dioxo-4-phenylimidazolidin-1- yl)acetamide  523 nM (0.83)

N-(4-bromophenyl)-2-(4-cyclopropyl-4- methyl-2,5-dioxoimidazolidin-1- yl)acetamide  166 nM (0.84)

N-(4-bromophenyl)-2-(2,4-dioxo-1,3- diazaspiro[4.6]undec-3-yl)acetamide  679 nM (0.96)

N-(4-bromophenyl)-2-(4-ethyl-4- methyl-2,5-dioxoimidazolidin-1- yl)acetamide  485 nM (1.0)

N-(4-chlorophenyl)-2-(4,4-diethyl-2,5- dioxoimidazolidin-1-yl)acetamide  314 nM (0.79)

2-(4,4-diethyl-2,5-dioxoimidazolidin-1- yl)-N-(4-fluorophenyl)acetamide 2771 nM (0.67)

N-(4-bromophenyl)-2-[4-methyl-2,5- dioxo-4-(2-phenylethyl)imidazolidin-1- yl]acetamide  860 nM (0.88)

N-(4-bromophenyl)-1,3,3a,4,7,7a- hexahydro-1,3-dioxo-4,7-methano-2H- isoindole-2-acetamide  575 (0.90)

N-(4-bromophenyl)-1,3,3a,4,7,7a- hexahydro-1,3-dioxo-2H-isoindole-2- acetamide  395 (0.98)

The compounds of Table 3 are available from Chemical Libraries such as Chemical Block Ltd.

In a further embodiment of the invention, there are provided methods for treating disorders associated with modulation of the FPR2.

Such methods can be performed, for example, by administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of at least one compound of the invention.

Therapeutic utilities of the FPR2 are ocular inflammatory diseases including, but not limited to, wet and dry age-related macular degeneration (ARMD), uveitis, dry eye, keratitis, allergic eye disease and conditions affecting the posterior part of the eye, such as maculopathies and retinal degeneration including non-exudative age related macular degeneration, exudative age related macular degeneration, choroidal neovascularization, diabetic retinopathy (proliferative), retinopathy of prematurity (ROP), acute macular neuroretinopathy, central serous chorioretinopathy, cystoid macular edema, and diabetic macular edema; infectious keratitis, herpetic keratitis, corneal angiogenesis, lymphangiogenesis, uveitis, retinitis, and choroiditis such as acute multifocal placoid pigment epitheliopathy, Behcet's disease, birdshot retinochoroidopathy, infectious (syphilis, lyme, tuberculosis, toxoplasmosis), intermediate uveitis (pars planitis), multifocal choroiditis, multiple evanescent white dot syndrome (mewds), ocular sarcoidosis, posterior scleritis, serpiginous choroiditis, subretinal fibrosis and uveitis syndrome, Vogt-Koyanagi-and Harada syndrome; vascular diseases/exudative diseases such as retinal arterial occlusive disease, central retinal vein occlusion, cystoids macular edema, disseminated intravascular coagulopathy, branch retinal vein occlusion, hypertensive fundus changes, ocular ischemic syndrome, retinal arterial microaneurysms, Coat's disease, parafoveal telangiectasis, hemi-retinal vein occlusion, papillophlebitis, central retinal artery occlusion, branch retinal artery occlusion, carotid artery disease (CAD), frosted branch angiitis, sickle cell retinopathy and other hemoglobinopathies, angioid streaks, familial exudative vitreoretinopathy, and Eales disease; traumatic/surgical conditions such as sympathetic ophthalmia, uveitic retinal disease, retinal detachment, trauma, post-surgical corneal wound healing, conditions caused by laser, conditions caused by photodynamic therapy, photocoagulation, hypoperfusion during surgery, radiation retinopathy, and bone marrow transplant retinopathy; proliferative disorders such as proliferative vitreal retinopathy and epiretinal membranes, and proliferative diabetic retinopathy; infectious disorders such as ocular histoplasmosis, ocular toxocariasis, presumed ocular histoplasmosis syndrome (POHS), endophthalmitis, toxoplasmosis, retinal diseases associated with HIV infection, choroidal disease associate with HIV infection, uveitic disease associate with HIV infection, viral retinitis, acute retinal necrosis, progressive outer retinal necrosis, fungal retinal diseases, ocular syphilis, ocular tuberculosis, diffuse unilateral subacute neuroretinitis, and myiasis; genetic disorders such as retinitis pigmentosa, systemic disorders with associated retinal dystrophies, congenital stationary night blindness, cone dystrophies, Stargardt's disease and fundus flavimaculatus, Best's disease, pattern dystrophy of the retinal pigmented epithelium, X-linked retinoschisis, Sorsby's fundus dystrophy, benign concentric maculopathy, Bietti's crystalline dystrophy, and pseudoxanthoma elasticum; retinal tears/holes such as retinal detachment, macular hole, and giant retinal tear; tumors such as retinal disease associated with tumors, congenital hypertrophy of the retinal pigmented epithelium, posterior uveal melanoma, choroidal hemangioma, choroidal osteoma, choroidal metastasis, combined hamartoma of the retina and retinal pigmented epithelium, retinoblastoma, vasoproliferative tumors of the ocular fundus, retinal astrocytoma, and intraocular lymphoid tumors; and miscellaneous other diseases affecting the posterior part of the eye such as punctate inner choroidopathy, acute posterior multifocal placoid pigment epitheliopathy, myopic retinal degeneration, and acute retinal pigment epitheliitis, systemic inflammatory diseases such as stroke, coronary artery disease, obstructive airway diseases, HIV-mediated retroviral infections, cardiovascular disorders including coronary artery disease, neuroinflammation, neurological disorders, pain and immunological disorders, asthma, allergic disorders, inflammation, systemic lupus erythematosus, psoriasis, CNS disorders such as Alzheimer's disease, arthritis, sepsis, inflammatory bowel disease, cachexia, angina pectoris, post-surgical corneal inflammation, blepharitis, MGD, dermal wound healing, burns, rosacea, atopic dermatitis, acne, psoriasis, seborrheic dermatitis, actinic keratoses, viral warts, photoaging rheumatoid arthritis and related inflammatory disorders, alopecia, glaucoma, branch vein occlusion, Best's vitelliform macular degeneration, retinitis pigmentosa, proliferative vitreoretinopathy (PVR), and any other degenerative disease of either the photoreceptors or the RPE (Perretti, Mauro et al. Pharmacology & Therapeutics 127 (2010) 175-188.)

These compounds are useful for the treatment of mammals, including humans, with a range of conditions and diseases that are alleviated by the modulation of FPR2: including, but not limited to the treatment of wet and dry age-related macular degeneration (ARMD), diabetic retinopathy (proliferative), retinopathy of prematurity (ROP), diabetic macular edema, uveitis, dry eye, retinal vein occlusion, cystoids macular edema, glaucoma, branch vein occlusion, Best's vitelliform macular degeneration, retinitis pigmentosa, proliferative vitreoretinopathy (PVR), and any other degenerative disease of either the photoreceptors or the RPE.

In still another embodiment of the invention, there are provided methods for treating disorders associated with modulation of the FPRL-1 receptor. Such methods can be performed, for example, by administering to a subject in need thereof a therapeutically effective amount of at least one compound of the invention, or any combination thereof, or pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual isomers, enantiomers, and diastereoisomers thereof.

The actual amount of the compound to be administered in any given case will be determined by a physician taking into account the relevant circumstances, such as the severity of the condition, the age and weight of the patient, the patient's general physical condition, the cause of the condition, and the route of administration.

The patient will be administered the compound orally in any acceptable form, such as a tablet, liquid, capsule, powder and the like, or other routes may be desirable or necessary, particularly if the patient suffers from nausea. Such other routes may include, without exception, transdermal, parenteral, subcutaneous, intranasal, via an implant stent, intrathecal, intravitreal, topical to the eye, back to the eye, intramuscular, intravenous, and intrarectal modes of delivery. Additionally, the formulations may be designed to delay release of the active compound over a given period of time, or to carefully control the amount of drug released at a given time during the course of therapy.

In another embodiment of the invention, there are provided pharmaceutical compositions including at least one compound of the invention in a pharmaceutically acceptable carrier thereof. The phrase “pharmaceutically acceptable” means the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

Pharmaceutical compositions of the present invention can be used in the form of a solid, a solution, an emulsion, a dispersion, a patch, a micelle, a liposome, and the like, wherein the resulting composition contains one or more compounds of the present invention, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for enteral or parenteral applications. Invention compounds may be combined, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. The carriers which can be used include glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextrans, and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form. In addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used. Invention compounds are included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or disease condition.

Pharmaceutical compositions containing invention compounds may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of a sweetening agent such as sucrose, lactose, or saccharin, flavoring agents such as peppermint, oil of wintergreen or cherry, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets containing invention compounds in admixture with non-toxic pharmaceutically acceptable excipients may also be manufactured by known methods. The excipients used may be, for example, (1) inert diluents such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; (2) granulating and disintegrating agents such as corn starch, potato starch or alginic acid; (3) binding agents such as gum tragacanth, corn starch, gelatin or acacia, and (4) lubricating agents such as magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.

In some cases, formulations for oral use may be in the form of hard gelatin capsules wherein the invention compounds are mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the invention compounds are mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.

Pharmaceutical compositions containing invention compounds may be in a form suitable for topical use, for example, as oily suspensions, as solutions or suspensions in aqueous liquids or nonaqueous liquids, or as oil-in-water or water-in-oil liquid emulsions.

Pharmaceutical compositions may be prepared by combining a therapeutically effective amount of at least one compound according to the present invention, or a pharmaceutically acceptable salt thereof, as an active ingredient with conventional ophthalmically acceptable pharmaceutical excipients and by preparation of unit dosage suitable for topical ocular use. The therapeutically efficient amount typically is between about 0.001 and about 5% (w/v), preferably about 0.001 to about 2.0% (w/v) in liquid formulations.

For ophthalmic application, preferably solutions are prepared using a physiological saline solution as a major vehicle. The pH of such ophthalmic solutions should preferably be maintained between 4.5 and 8.0 with an appropriate buffer system, a neutral pH being preferred but not essential. The formulations may also contain conventional pharmaceutically acceptable preservatives, stabilizers and surfactants. Preferred preservatives that may be used in the pharmaceutical compositions of the present invention include, but are not limited to, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate and phenylmercuric nitrate. A preferred surfactant is, for example, Tween 80. Likewise, various preferred vehicles may be used in the ophthalmic preparations of the present invention. These vehicles include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose cyclodextrin and purified water.

Tonicity adjustors may be added as needed or convenient. They include, but are not limited to, salts, particularly sodium chloride, potassium chloride, mannitol and glycerin, or any other suitable ophthalmically acceptable tonicity adjustor.

Various buffers and means for adjusting pH may be used so long as the resulting preparation is ophthalmically acceptable. Accordingly, buffers include acetate buffers, citrate buffers, phosphate buffers and borate buffers. Acids or bases may be used to adjust the pH of these formulations as needed.

In a similar manner, an ophthalmically acceptable antioxidant for use in the present invention includes, but is not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene.

Other excipient components which may be included in the ophthalmic preparations are chelating agents. The preferred chelating agent is edentate disodium, although other chelating agents may also be used in place of or in conjunction with it.

The ingredients are usually used in the following amounts:

Ingredient Amount (% w/v) active ingredient about 0.001-5 preservative   0-0.10 vehicle 0-40 tonicity adjustor 0-10 buffer 0.01-10    pH adjustor q.s. pH 4.5-7.8 antioxidant as needed surfactant as needed purified water to make 100%

The actual dose of the active compounds of the present invention depends on the specific compound, and on the condition to be treated; the selection of the appropriate dose is well within the knowledge of the skilled artisan.

The ophthalmic formulations of the present invention are conveniently packaged in forms suitable for metered application, such as in containers equipped with a dropper, to facilitate application to the eye. Containers suitable for dropwise application are usually made of suitable inert, non-toxic plastic material, and generally contain between about 0.5 and about 15 ml solution. One package may contain one or more unit doses. Especially preservative-free solutions are often formulated in non-resealable containers containing up to about ten, preferably up to about five units doses, where a typical unit dose is from one to about 8 drops, preferably one to about 3 drops. The volume of one drop usually is about 20-35 μl.

The pharmaceutical compositions may be in the form of a sterile injectable suspension. This suspension may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides, fatty acids (including oleic acid), naturally occurring vegetable oils like sesame oil, coconut oil, peanut oil, cottonseed oil, etc., or synthetic fatty vehicles like ethyl oleate or the like. Buffers, preservatives, antioxidants, and the like can be incorporated as required.

The compounds of the invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions may be prepared by mixing the invention compounds with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters of polyethylene glycols, which are solid at ordinary temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.

Since individual subjects may present a wide variation in severity of symptoms and each drug has its unique therapeutic characteristics, the precise mode of administration and dosage employed for each subject is left to the discretion of the practitioner.

The compounds and pharmaceutical compositions described herein are useful as medicaments in mammals, including humans, for treatment of diseases and/or alleviations of conditions which are responsive to treatment by agonists or functional antagonists of FPR2. Thus, in further embodiments of the invention, there are provided methods for treating a disorder associated with modulation of FPR2. Such methods can be performed, for example, by administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of at least one invention compound. As used herein, the term “therapeutically effective amount” means the amount of the pharmaceutical composition that will elicit the biological or medical response of a subject in need thereof that is being sought by the researcher, veterinarian, medical doctor or other clinician. In some embodiments, the subject in need thereof is a mammal. In some embodiments, the mammal is human.

Materials and Methods

FPR2 agonists would be expected to have significant effects in many different types of ocular inflammation, but have been exemplified by demonstrating anti-inflammatory activity in endotoxin-induced uveitis in rats (FIGS. 1 and 2). Anti-inflammatory activity in this model has been exemplified with the FPR2 agonists described in Table 4.

FLIPR: HEK-Gα16 cells stably expressing the human FPR2 receptor was utilized. Cells were plated into 384-well poly-D-lysine coated plates at a density of 18,000 cells per well one day prior to use. The growth media was DMEM medium supplemented with 10% fetal bovine serum (FBS), 1% antibiotic-antimycotic, 50 μg/ml hygromycin, and 400 μg/ml geneticin. On the day of the experiment, the cells were washed twice with Hank's Balanced Salt Solution supplemented with 20 mM HEPES (HBSS/hepes buffer). The cells were then dye loaded with 2 μM Fluo-4 diluted in the HBSS/Hepes buffer and incubated at 37° C. for 40 minutes. Extracellular dye was removed by washing the cell plates four times prior to placing the plates in the FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices). Ligands were diluted in HBSS/Hepes buffer and prepared in 384-well microplates. Data for Ca⁺² responses were obtained in relative fluorescence units.

TABLE 4 Com- pound FPR2 num- EC₅₀ ber Structure IUPAC name (efficacy) 1

1-(4-bromophenyl)-3-[4- ethyl-2,5-dioxo-4-(2- phenylethyl)imidazolidin- 1-yl]urea  3.0 (0.96) 2

{[(2S)-2-{[(4- bromophenyl)carbamoyl] amino}pentanoyl]amino} acetic acid  2 (0.91) 3

{[(2S,3S)-2-{[(4- bromophenyl)carbamoyl] amino}-3- methylpentanoyl]amino} acetic acid  1.98 (1.0) 4

1-(4-bromophenyl)-3-[4- ethyl-2,5-dioxo-4- (propan-2-yl) imidazolidin-1-yl]urea  6.7 (0.90) 5

(2S,3S)-2-{[(4-bromo-2- fluorophenyl)carbamoyl] amino}-3-methylpentanoic acid  31 (0.96) 6

2-{[(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-4-methylpentanoyl] amino}-2-methylpropanoic acid  1.66 (0.91) 7

{[(2S)-2-{[(4-bromo-2- fluorophenyl)carbamoyl] amino}-4-methylpentanoyl] amino}acetic acid  3.57 (1.0) 8

{[(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-4-methylpentanoyl] amino}acetic acid  0.78 (0.78) 9

(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-4-methylpentanoic acid  5.95 (0.77) 10

2-{[(4- bromophenyl)carbamoyl] amino}-N-(2-oxoazepan- 3-yl)-3- phenylpropanamide  11 nM (0.89) 11

3-[(4- iodophenyl)carbamoyl] spiro[bicyclo[2.2.1] heptane-7,1′- cyclopropane]-5-ene-2- carboxylic acid  1.6 nM (1.00) 12

3-[(4- bromophenyl)carbamoyl] spiro[bicyclo[2.2.1] heptane-7,1′- cyclopropane]-5-ene-2- carboxylic acid  4 nM (0.97) 13

1-(4-acetylphenyl)-3-{3-(4- cyanophenyl)-2-[2-(1H- imidazol-4-yl)ethyl]-1- oxo-1,2,3,4- tetrahydroisoquinolin-7- yl}urea  11 nM (0.80) 14

rel-(2R,3S)-3-[(4- bromophenyl)carbamoyl] spiro[bicyclo[2.2.1] heptane-7,1′- cyclopropane]-2- carboxylic acid  4 nM (0.90) 15

3-[(4- iodophenyl)carbamoyl] spiro[bicyclo[2.2.1] heptane-7,1′- cyclopropane]-2- carboxylic acid  0.60 nM (0.87) 16

1-[2-(3-aminopropyl)-3- (4-cyanophenyl)-1-oxo- 1,2,3,4- tetrahydroisoquinolin-7- yl]-3-[4-(methylsulfanyl) phenyl]urea  2.5 nM (0.70) 17

1-{3-(4-cyanophenyl)-2- [2-(1H-imidazol-4-yl) ethyl]-1-oxo-1,2,3,4- tetrahydroisoquinolin-7- yl}-3-[4-(methylsulfanyl) phenyl]urea  5.5 nM (0.92) 18

1-[2-(3-aminopropyl)-3- (4-cyanophenyl)-1-oxo- 1,2,3,4- tetrahydroisoquinolin- 7-yl]-3-[4- (methylsulfonyl)phenyl] urea  10 nM (0.86) 19

1-{3-(4-cyanophenyl)- 2-[2-(1H-imidazol-4-yl) ethyl]-1-oxo-1,2,3,4- tetrahydroisoquinolin- 7-yl}-3-[4- (methylsulfonyl)phenyl] urea  20 nM (1.00) 20

3-[(4-iodophenyl) carbamoyl]-7- (propan-2-ylidene) bicyclo[2.2.1]hept-5- ene-2-carboxylic acid  11 nM (0.94) 21

3-[(4-bromophenyl) carbamoyl]-7,7- dimethylbicyclo[2.2.1] heptane-2-carboxylic acid  10 nM (0.85) 22

3-[(4-iodophenyl) carbamoyl]-7,7- dimethylbicyclo[2.2.1] heptane-2-carboxylic acid  1.7 nM (0.97) 23

1-{3-(furan-2-yl)-2-[2- (1H-imidazol-4-yl)ethyl]- 1-oxo-1,2,3,4- tetrahydroisoquinolin- 7-yl}-3-[4- (methylsulfanyl)phenyl] urea  19 nM (0.83) 24

1-{3-(5-fluoropyridin-2- yl)-2-[2-(1H-imidazol- 4-yl)ethyl]-1-oxo-1,2,3,4- tetrahydroisoquinolin- 7-yl}-3-[4- (methylsulfinyl)phenyl] urea  11.8 nM (0.93) 25

1-{3-(5-fluoropyridin-2- yl)-2-[2-(1H-imidazol- 4-yl)ethyl]-1-oxo-1,2,3,4- tetrahydroisoquinolin- 7-yl}-3-[4- (methylsulfonyl)phenyl] urea  10.5 nM (1.0) 26

N-(4- bromophenyl)spiro [bicyclo[2.2.1]heptane- 7,1′-cyclopropane]-5- ene-2,3-dicarboxamide  4.8 nM (0.91) 27

1-{3-(5-chlorofuran-2- yl)-2-[2-(1H-imidazol- 4-yl)ethyl]-1- oxo-1,2,3,4- tetrahydroisoquinolin- 7-yl}-3-[4- (methylsulfanyl)phenyl] urea  17 nM (0.81) 28

1-{3-(6-chloropyridin-3- yl)-2-[2-(1H-imidazol- 4-yl)ethyl]-1- oxo-1,2,3,4- tetrahydroisoquinolin- 7-yl}-3-[4- (methylsulfanyl)phenyl] urea  6.3 nM (0.89) 29

3-{[4-(methylsulfanyl) phenyl]carbamoyl} spiro[bicyclo[2.2.1] heptane-7,1′- cyclopropane]-2- carboxylic acid  7 nM (0.96) 30

N-(4-bromophenyl) spiro[bicyclo[2.2.1] heptane-7,1′- cyclopropane]-2,3- dicarboxamide  2.5 nM (0.96) 31

3-{[4-(methylsulfanyl) phenyl]carbamoyl} spiro[bicyclo[2.2.1] heptane-7,1′- cyclopropane]-5-ene- 2-carboxylic acid  14 nM (0.85) 32

1-{3-(5-chloropyridin- 2-yl)-2-[2-(1H-imidazol- 4-yl)ethyl]-1- oxo-1,2,3,4- tetrahydroisoquinolin- 7-yl}-3-[4- (methylsulfanyl)phenyl] urea  13.5 nM (0.91) 33

1-{3-(5-chloropyridin- 2-yl)-2-[2-(1H-imidazol- 4-yl)ethyl]-1- oxo-1,2,3,4- tetrahydroisoquinolin- 7-yl}-3-[4- (methylsulfonyl)phenyl] urea  9.5 nM (0.99) 34

N-(4-bromophenyl)-7,7- dimethylbicyclo[2.2.1] heptane-2,3-dicarboxamide  15 nM (0.83) 35

N-(4-iodophenyl)-7,7- dimethylbicyclo[2.2.1] heptane-2,3-dicarboxamide  2.6 nM (0.81) 36

(+)1-[(3R)-2-(3- aminopropyl)-3-(4- cyanophenyl)-1- oxo-1,2,3,4- tetrahydroisoquinolin- 7-yl]-3-[4- (methylsulfanyl)phenyl] urea  3.3 nM (0.97) 37

7,7-dimethyl-N-[4- (methylsulfanyl)phenyl] bicyclo[2.2.1]heptane- 2,3-dicarboxamide  17 nM (0.85) 38

N-(4-iodophenyl)spiro [bicyclo[2.2.1]heptane- 7,1′-cyclopropane]-2,3- dicarboxamide  1.9 nM (0.95) 39

N-(4-iodophenyl)spiro [bicyclo[2.2.1]heptane- 7,1′-cyclopropane]-5- ene-2,3-dicarboxamide  1.6 nM (0.90) 40

(+) tert-butyl {3-[(3R)- 3-(4-cyanophenyl)-7- ({[4-(methylsulfinyl) phenyl]carbamoyl} amino)-1-oxo-3,4- dihydroisoquinolin- 2(1H)-yl]propyl} carbamate 103 nM (0.91) 41

(+) 1-[(3R)-2-(3- aminopropyl)-3-(4- cyanophenyl)-1- oxo-1,2,3,4- tetrahydroisoquinolin- 7-yl]-3-[4- (methylsulfinyl)phenyl] urea  10.6 nM (0.94) 42

1-[2-(3-aminopropyl)- 3-methyl-1-oxo-1,2,3,4- tetrahydroisoquinolin- 7-yl]-3-[4- (methylsulfanyl)phenyl] urea  15 nM (1.00) 43

1-[2-(3-aminopropyl)- 3-(4-cyanophenyl)- 1-oxo-1,2,3,4- tetrahydroisoquinolin- 7-yl]-3-(4-iodophenyl) urea  13.7 nM (0.94) 44

(+) (2S,3R)-3-[(4- bromophenyl)carbamoyl] spiro[bicyclo[2.2.1] heptane-7,1′- cyclopropane]-2- carboxylic acid  <1 nM (0.98) 45

(−) N-(4-bromophenyl) spiro[bicyclo[2.2.1] heptane-7,1′- cyclopropane]-2,3- dicarboxamide  <1 nM (0.91) 46

N-(4-bromophenyl)-N′- methylspiro[bicyclo [2.2.1]heptane-7,1′- cyclopropane]-2,3- dicarboxamide   8.5 nM (1.0) 47

N-(4-bromophenyl)-N′- ethylspiro[bicyclo[2.2.1] heptane-7,1′- cyclopropane]-2,3- dicarboxamide   9.3 nM (1.0) 48

N-(4-bromophenyl)-N′- (propan-2-yl)spiro [bicyclo[2.2.1]heptane- 7,1′-cyclopropane]-2,3- dicarboxamide   6.7 nM (1.0) 49

1-(4-bromophenyl)-3- (4,4-diethyl-2,5- dioxoimidazolidin- 1-yl)urea  11.5 nM (0.98) 50

1-(4-bromo-2- fluorophenyl)-3- (4,4-diethyl-2,5- dioxoimidazolidin- 1-yl)urea  15.7 nM (1.0) 51

(2S)-2-{[(4- iodophenyl)carbamoyl] amino}-3- phenylpropanoic acid  14.5 nM (1.0) 52

1-(4-bromophenyl)-3- (2,4-dioxo-1,3- diazaspiro[4.5]dec-3- yl)urea  15.1 nM (1.0) 53

(2S,3S)-2-{[(4- bromophenyl)carbamoyl] amino}-3- methylpentanoic acid  12.9 nM (0.9) 54

1-(4-bromophenyl)-3- [4-methyl-2,5-dioxo- 4-(2-phenylethyl) imidazolidin-1- yl]urea   5.1 nM (0.87) 55

{[(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-3- phenylpropanoyl]amino} acetic acid   7.7 nM (0.99) 56

3-{[(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-3- phenylpropanoyl]amino} propanoic acid  18 nM (0.98) 57

(+) 1-(4-bromophenyl)- 3-[4-methyl-2,5- dioxo-4-(2-phenylethyl) imidazolidin-1- yl]urea   3.2 nM (0.93) 58

(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-N-(2- hydroxyethyl)-3- phenylpropanamide   7.0 nM (0.86) 59

{[(2S,3S)-2-{[(4- bromo-2-fluorophenyl) carbamoyl]amino}-3- methylpentanoyl]amino} acetic acid   5.5 nM (0.95) 60

(2S,3S)-N-(2-amino-2- oxoethyl)-2-{[(4- bromophenyl)carbamoyl] amino}-3- methylpentanamide   4.6 nM (0.91) 61

1-(4-bromo-2- fluorophenyl)-3-[4- ethyl-2,5-dioxo-4- (propan-2-yl) imidazolidin-1-yl] urea   9.2 nM (0.97) 62

(2S,3S)-N-(2-amino- 2-oxoethyl)-2-{[(4- bromo-2-fluorophenyl) carbamoyl]amino}-3- methylpentanamide  10.3 nM (1.0) 63

(2S,3S)-2-{[(4- bromophenyl)carbamoyl] amino}-3-methyl-N-(2- oxopropyl)pentanamide  10.5 nM (0.97) 64

1-(4-bromophenyl)-3- [2,5-dioxo-4,4-di (propan-2-yl) imidazolidin-1-yl] urea   3.8 nM (1.0) 65

1-(4-bromophenyl)-3- (4,4-dicyclopropyl-2,5- dioxoimidazolidin- 1-yl)urea  14.3 nM (1.0) 66

(+)1-(4-bromophenyl)- 3-[4-ethyl-2,5-dioxo- 4-(propan-2-yl) imidazolidin-1-yl]urea   4.3 nM (0.96) 67

(−)1-(4-bromophenyl)- 3-[4-ethyl-2,5-dioxo- 4-(propan-2-yl) imidazolidin-1-yl]urea   3.3 nM (1.0) 68

(2S)-2-{[(4-bromo-2- fluorophenyl)carbamoyl] amino}-N-(2- oxopropyl)-3- phenylpropanamide  12.4 nM (0.94) 69

1-(4-bromo-2- fluorophenyl)-3- [4-ethyl-2,5-dioxo- 4-(2-phenylethyl) imidazolidin-1- yl]urea  13.4 nM (0.91) 70

(2S)-2-{[(4- bromophenyl)carbamoyl] amino}pentanoic acid   7.1 nM (1.0) 71

(2S)-2-{[(4-bromo-2- fluorophenyl)carbamoyl] amino}-N-(2- hydroxyethyl)-3- phenylpropanamide  15.6 nM (0.98) 72

methyl {[(2S)-2-{[(4- bromophenyl)carbamoyl] amino}pentanoyl]amino} acetate  16.4 nM (0.86) 73

propan-2-yl {[(2S)-2- {[(4-bromophenyl) carbamoyl]amino} pentanoyl]amino} acetate  14.5 nM (1.0) 74

{[(2S)-2-{[(4-bromo- 2-fluorophenyl) carbamoyl]amino} pentanoyl]amino} acetic acid   4.1 nM (0.91) 75

(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-N-(2- hydroxyethyl)-4- methylpentanamide  13.5 nM (0.76) 76

1-(4-bromophenyl)-3-{4-[2- (furan-2-yl)ethyl]-4-methyl- 2,5-dioxoimidazolidin-1- yl}urea   5.2 nM (0.99) 77

(2S)-N-(2-amino-2- oxoethyl)-2-{[(4- bromophenyl)carbamoyl] amino}-4- methylpentanamide   1.1 nM (1.0) 78

(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-4-methyl-N-(2- oxopropyl)pentanamide   4.7 nM (0.82) 79

(2S)-N-(2-amino-2- oxoethyl)-2-{[(4- bromophenyl)carbamoyl] amino}pentanamide   2.5 nM (0.97) 80

1-(4-bromophenyl)-3- {4-[2-(2-fluorophenyl) ethyl]-4-methyl-2,5- dioxoimidazolidin-1- yl}urea  14.3 nM (99) 81

(2S)-N-(2-amino-2- oxoethyl)-2-{[(4-bromo- 2-fluorophenyl) carbamoyl]amino} pentanamide   5.2 nM (0.96) 82

1-(4-bromophenyl)-3- {4-[2-(4-fluorophenyl) ethyl]-4-methyl-2,5- dioxoimidazolidin-1- yl}urea  16.3 nM (1.0) 83

1-(4-bromophenyl)-3- {4-[2-(3-fluorophenyl) ethyl]-4-methyl-2,5- dioxoimidazolidin-1- yl}urea  11.1 nM (1.0) 84

(2S)-N-(2-amino-2- oxoethyl)-2-{[(4- bromo-2-fluorophenyl) carbamoyl]amino}-4- methylpentanamide   4.5 nM (0.95) 85

(2S)-2-{[(4-bromo-2- fluorophenyl)carbamoyl] amino}-4-methyl-N-(2- oxopropyl)pentanamide  20 nM (0.99) 86

1-(4-bromophenyl)-3- {4-[2-(4-hydroxyphenyl) ethyl]-4-methyl-2,5- dioxoimidazolidin-1- yl}urea  13.3 nM (1.0) 87

(2S)-2-{[(2S)-2-{[(4- bromo-2-fluorophenyl) carbamoyl]amino}-4- methylpentanoyl] amino}propanoic acid  12.1 nM (0.95) 88

1-(4-bromophenyl)-3- {4-methyl-2,5-dioxo- 4-[2-(thiophen-2-yl) ethyl]imidazolidin- 1-yl}urea   7.9 nM (0.94) 89

1-(4-bromo-2- fluorophenyl)-3-{4- [2-(4-hydroxyphenyl) ethyl]-4-methyl-2,5- dioxoimidazolidin-1- yl}urea   8.7 nM (0.85) 90

(2S)-2-{[(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-4- methylpentanoyl]amino} propanoic acid  11.6 nM (1.0) 91

(2S)-2-{[(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-4- methylpentanoyl] amino}-3- methylbutanoic acid   1.7 nM (0.97) 92

(2S)-N-[(2S)-1-amino- 3-methyl-1-oxobutan- 2-yl]-2-{[(4- bromophenyl)carbamoyl] amino}-4- methylpentanamide   5.8 nM (1.0) 93

(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-N-(2-hydroxy-2- methylpropyl)-4- methylpentanamide   2.5 nM (0.93) 94

(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-N-(1,3- dihydroxypropan-2-yl)- 4-methylpentanamide   7.4 nM (0.96) 95

(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-N-(2,3- dihydroxypropyl)-4- methylpentanamide   5.1 nM (0.98) 96

(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-N-[(2R)-1- hydroxypropan-2-yl]-4- methylpentanamide   3.0 nM (1.0) 97

1-(4-bromophenyl)-3- {4-methyl-4-[2-(5- methylfuran-2-yl)ethyl]- 2,5-dioxoimidazolidin- 1-yl}urea   3.5 nM (0.95) 98

1-(4-bromo-2- fluorophenyl)-3-{4-[2- (3-fluoro-4- hydroxyphenyl)ethyl]- 4-methyl-2,5- dioxoimidazolidin-1- yl}urea   7.4 nM (0.91) 99

1-(4-bromophenyl)-3- {4-[2-(3-fluoro-4- hydroxyphenyl)ethyl]- 4-methyl-2,5- dioxoimidazolidin-1- yl}urea   8.0 nM (1.0) 100

tert-butyl (2S)-2- {[(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-4- methylpentanoyl]amino} pentanoate  13.0 nM (1.0) 101

(2S)-2-{[(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-4- methylpentanoyl]amino} pentanoic acid   1.0 nM (0.95) 102

(2S)-N-[(2S)-1-amino- 1-oxopentan-2-yl]-2- {[(4-bromophenyl) carbamoyl]amino}-4- methylpentanamide   7.3 nM (0.99) 103

(2S)-{[(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-4- methylpentanoyl]amino} (phenyl)ethanoic acid   9.1 nM (1.0) 104

(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-4-methyl-N- (1H-tetrazol-5-ylmethyl) pentanamide   2.3 nM (0.81) 105

ethyl hydrogen ({[(2S)- 2-{[(4-bromophenyl) carbamoyl]amino}-4- methylpentanoyl] amino}methyl) phosphonate   0.95 nM (0.88) 106

1-(4-bromo-2- fluorophenyl)-3-{4- [2-(2-hydroxyphenyl) ethyl]-4-methyl-2,5- dioxoimidazolidin-1- yl}urea   4.0 nM (0.91) 107

1-(4-bromo-2- fluorophenyl)-3-{4- [2-(3-hydroxyphenyl) ethyl]-4-methyl-2,5- dioxoimidazolidin-1- yl}urea   2.2 nM (0.79) 108

1-(4-bromophenyl)-3- {4-[2-(3-hydroxyphenyl) ethyl]-4-methyl-2,5- dioxoimidazolidin-1- yl}urea   2.1 nM (1.0) 109

1-(4-bromophenyl)-3- {4-[2-(2-hydroxyphenyl) ethyl]-4-methy1-2,5- dioxoimidazolidin-1- yl}urea   0.97 nM (0.93) 110

2-{[(4-bromophenyl) carbamoyl]amino}-2,4- dimethylpentanoic acid  19.4 nM (0.98) 111

[(2-{[(4-bromophenyl) carbamoyl]amino}-2,4- dimethylpentanoyl) amino]acetic acid  19.1 nM (0.99) 112

diethyl ({[(2S)-2- {[(4-bromophenyl) carbamoyl]amino}-4- methylpentanoyl] amino}methyl) phosphonate   0.48 nM (0.95) 113

(2-{[(4-bromophenyl) carbamoyl]amino}-2- ethylbutanoyl)amino] acetic acid  18.7 nM (1.0) 114

diethyl ({[(2S,3S)-2- {[(4-bromophenyl) carbamoyl]amino}-3- methylpentanoyl] amino}methyl) phosphonate   2.9 nM (1.0) 115

ethyl hydrogen ({[(2S,3S)-2-{[(4- bromophenyl)carbamoyl] amino}-3- methylpentanoyl]amino} methyl)phosphonate   2.7 nM (0.88) 116

(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-N-[(3-hydroxy- 1,2-oxazol-5-yl)methyl]- 4-methylpentanamide  12.0 nM (1.0) 117

diethyl ({[(2S)-2-{[(4- bromophenyl)carbamoyl] amino}pentanoyl]amino} methyl)phosphonate   0.27 nM (1.0) 118

diethyl ({[(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-3- phenylpropanoyl]amino} methyl)phosphonate  16.1 nM (0.93) 119

diethyl (2-{[(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-4- methylpentanoyl]amino} ethyl)phosphonate  16.1 nM (0.97) 120

(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-N-[2- (dimethylamino)-2- oxoethyl]-4- methylpentanamide   1.7 nM (0.99) 121

(2S)-2-{[(4- iodophenyl)carbamoyl] amino}-4- methylpentanoic acid   4.0 nM (0.93) 122

(2R,3R)-2-{[(4- bromophenyl)carbamoyl] amino}-3- methylpentanoic acid  10 □M (0.59) 123

ethyl hydrogen ({[(2S)- 2-{[(4-bromophenyl) carbamoyl]amino} pentanoyl]amino} methyl)phosphonate   1 nM (0.96) 124

{[(2S)-4-methyl-2-({[4- (trifluoromethyl)phenyl] carbamoyl}amino) pentanoyl]amino} acetic acid   1.8 nM (1.0) 125

dipropan-2-yl ({[(2S)- 2-{[(4-bromophenyl) carbamoyl]amino} pentanoyl]amino} methyl)phosphonate   1.2 nM (1.0) 126

ethyl hydrogen ({[(2S)- 2-{[(4-bromophenyl) carbamoyl]amino}-3- phenylpropanoyl]amino} methyl)phosphonate  16.0 nM (1.0) 127

{[(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-4- methylpentanoyl]amino} methanesulfonic acid   2.0 nM (0.91) 128

(2S)-4-methyl-2-({[4- (methylsulfanyl)phenyl] carbamoyl}amino) pentanoic acid  16.8 nM (0.92) 129

propan-2-yl hydrogen {[(2-{[(4-bromophenyl) carbamoyl]amino} pentanoyl)amino] methyl}phosphonate   1.87 nM (0.89) 130

{[(2S)-4-methyl-2- ({[4-(methylsulfanyl) phenyl]carbamoyl} amino)pentanoyl] amino}acetic acid   3.0 nM (1.0) 131

dipropan-2-yl ({[(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-4- methylpentanoyl]amino} methyl)phosphonate   4.0 nM (1.0) 132

1-(4-bromophenyl)-3- [4-(hydroxymethyl)- 2,5-dioxo-4-(propan- 2-yl)imidazolidin-1- yl]urea  16.2 nM (0.86) 133

2-[1-{[(4- bromophenyl)carbamoyl] amino}-2,5-dioxo-4- (propan-2-yl) imidazolidin-4-yl]-N- (2-hydroxyethyl) acetamide   2.7 nM (1.0) 134

diethyl ({[(2S)-4- methyl-2-({[4- (trifluoromethyl)phenyl] carbamoyl}amino) pentanoyl]amino} methyl)phosphonate   5.5 nM (0.97) 135

ethyl hydrogen ({[(2S)- 4-methyl-2-({[4- (trifluoromethyl)phenyl] carbamoyl}amino) pentanoyl]amino} methyl)phosphonate   1.9 nM (0.91) 136

(2S)-4-methyl-N- (1H-tetrazol-5- ylmethyl)-2-({[4- (trifluoromethyl)phenyl] carbamoyl}amino) pentanamide   3.7 nM (0.96) 137

{[(2S)-4-methyl-2- ({[4-(trifluoromethyl) phenyl]carbamoyl} amino)pentanoyl] amino} methanesulfonic acid   1.9 nM (0.99) 138

diethyl ({[(2S)-4- methyl-2-({[4- (methylsulfanyl)phenyl] carbamoyl}amino) pentanoyl]amino} methyl)phosphonate   3.5 nM (0.91) 139

2-methyl-2-{[(2S)- 4-methyl-2-({[4- (trifluoromethyl)phenyl] carbamoyl}amino) pentanoyl]amino} propanoic acid   2.5 nM (0.92) 140

tert-butyl (2S)-2-{[(4- bromophenyl)sulfamoyl] amino}-4- methylpentanoate NA 141

methyl 2-[2-(1-{[(4- bromophenyl)carbamoyl] amino}-4-ethyl-2,5- dioxoimidazolidin-4- yl)ethyl]benzoate  10.3 nM (0.92) 142

2-[1-{[(4- bromophenyl)carbamoyl] amino}-2,5-dioxo-4- (propan-2-yl) imidazolidin-4-yl]-N- (1,3-dihydroxypropan- 2-yl)acetamide  13.8 nM (0.92) 143

2-[2-(1-{[(4- bromophenyl)carbamoyl] amino}-4-ethyl-2,5- dioxoimidazolidin-4- yl)ethyl]benzoic acid  17.2 nM (1.0) 144

{[(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-4- (methylsulfanyl)butanoyl] amino}acetic acid   6.3 nM (0.91) 145

3-({[1-{[(4-bromo-2- fluorophenyl)carbamoyl] amino}-2,5-dioxo-4- (propan-2-yl) imidazolidin-4-yl]acetyl} amino)propanoic acid   1.0 nM (1.0) 146

2-[2-(1-{[(4-bromo-2- fluorophenyl)carbamoyl] amino}-4-ethyl-2,5- dioxoimidazolidin-4-yl) ethyl]benzoic acid  11.1 nM (1.0) 147

3-({[1-{[(4- bromophenyl)carbamoyl] amino}-2,5-dioxo-4- (propan-2-yl) imidazolidin-4-yl] acetyl}amino) propanoic acid   3.9 nM (0.99) 148

2-[1-{[(4-bromo-2- fluorophenyl)carbamoyl] amino}-2,5-dioxo-4- (propan-2-yl) imidazolidin-4-yl]-N- (2-hydroxyethyl) acetamide   6.9 nM (0.98) 149

ethyl 3-[1-{[(4- bromophenyl)carbamoyl] amino}-2,5-dioxo-4- (propan-2-yl) imidazolidin-4-yl] propanoate   6.6 nM (0.94) 150

{[2-{[(4- bromophenyl)carbamoyl] amino}-3-(1H-indol-3- yl)propanoyl]amino} acetic acid   1.4 nM (0.98) 151

2-{2-[1-{[(4- bromophenyl)carbamoyl] amino}-2,5-dioxo-4- (propan-2-yl) imidazolidin-4-yl] ethyl}benzoic acid   5.8 nM (1.0) 152

diethyl [2-({[1-{[(4- bromophenyl)carbamoyl] amino}-2,5-dioxo-4- (propan-2-yl) imidazolidin-4-yl] acetyl}amino)ethyl] phosphonate  11 nM (1.0) 153

ethyl 3-{[(4- bromophenyl)carbamoyl] amino}-2,4-dioxo-1,3- diazaspiro[4.5]decane- 8-carboxylate  12 nM (0.99) 154

tert-butyl {[(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-4- methylpentanoyl] (methyl)amino}acetate  12 nM (0.85) 155

{[(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-4- methylpentanoyl] (methyl)amino}acetic acid   1.0 nM (1.0)

Immunohistochemistry: Chromogenic DAB immunohistochemistry with antibodies specific to FPR2 was used to determine localization in normal human, primate, and rat eyes. Anti-FPR2 antibody (Abcam) was used at a dilution of 1:200 to detect FPR2 protein in all species.

Endotoxin-induced uveitis in rats: Uveitis is a harmful ocular inflammatory condition in humans. Anterior uveitis is a recurrent inflammatory disease and may have potentially blinding consequence. The pathogenesis of the disease is poorly understood, and the anti-inflammatory therapy used is non-specific and is associated with significant complications. Animal models are key to understanding the disease and testing novel therapies. A single low dose of lipopolysaccharide (LPS) in the footpad induces anterior uveitis in rats. This model known as endotoxin-induced uveitis serves as a useful paradigm of human anterior uveitis. Male Lewis rats (260±25 grams) were purchased from Charles River Laboratory. Rats were footpad-injected (hind left side) with 100 μl of 1 mg/ml LPS (List Biological Labs) solution (in sterile 0.9% saline). Test compounds were formulated in the vehicle consisting of sodium phosphate, dibasic heptahydrate, salts, CMC and sterile water. Compounds were topically (0.1-1%) or subcutaneously (10 mg/kg) dosed 2 hr after LPS. Animals were sacrificed at 24 hours following LPS injection. Aqueous humor was collected and analyzed to determine inflammatory cell counts and total protein concentrations.

Alkali burn in rabbits: Corneal epithelium plays an important role in the maintenance of corneal function and integrity. Prolonged corneal epithelial defects causes corneal opacity, neovascularization, bacterial infection and visual loss. Corneal epithelial healing is a complex process involving inflammatory response to injury, cell proliferation and migration. Animal models of corneal injury are every useful to test new anti-inflammatory and pro-wound healing therapies. New Zealand White rabbits weighing between 2.1 and 2.5 kg were anesthetized systemically with Ketamine/Xylazine (35/5 mg/kg) subcutaneously and topically with proparacaine (0.5%). The corneal epithelial wound in one eye was induced with a NaOH saturated filter paper containing 1.0 N NaOH for 30 seconds. The eyes were rinsed with sterile PBS. The corneal wound was confirmed by fluorescein staining with 10% sodium fluorescein (Science Lab Com) and slit lamp photography. Test compounds were formulated in the vehicle described above. For initial studies compounds were topically dosed three times a day. Quantification of corneal wound areas was done using Image J software where fluorescing stain green part was traced and converted to total pixel.

The compounds below would be expected to have significant effects in many different types of ocular inflammation, but have been exemplified by demonstrating anti-inflammatory activity in endotoxin-induced uveitis in rats (FIGS. 1 and 2). Anti-inflammatory activity in this model has been exemplified with the following FPR2 agonists.

In this model the compounds show a strong anti-inflammatory activity in blocking the infiltration of neutrophils and protein into the anterior chamber. In addition FPR2 agonists show accelerated healing and re-epithelialization in mouse models of corneal wound as exemplified by compound {[(2S,3S)-2-{[(4-bromophenyl)carbamoyl]amino}-3-methylpentanoyl]amino}acetic acid in (FIG. 3). These data demonstrate that FPR2 agonists are potent and efficacious anti-inflammatory agents suitable for ocular use in different models of ocular inflammation. 

What is claimed is:
 1. A method of treating an ocular inflammatory disease in a subject in need of such treatment, wherein the method comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one formyl peptide receptor 2 (FPR2) agonist to the subject; wherein the ocular inflammatory disease is selected from the group consisting of uveitis, dry eye, keratitis, allergic eye disease, infectious keratitis, herpetic keratitis, corneal angiogenesis, lymphangiogenesis, retinitis, choroiditis, acute multifocal placoid pigment epitheliopathy, Behcet's disease, post-surgical corneal wound healing, wet age-related macular degeneration (ARMD) and dry ARMD; and wherein the FPR2 agonist is a compound represented by Formula III, or a pharmaceutically acceptable salt thereof:

wherein: R¹ is halogen, hydrogen, optionally substituted C₁₋₈ alkyl, OR⁹, C(O)R¹⁰, NO₂, NR¹³R¹⁴, CN, SR¹⁵ or SO₂R¹⁶; R² is halogen, optionally substituted C₁₋₈ alkyl, CF₃, OR⁹, C(O)R¹⁰, NO₂, NR¹³R¹⁴, CN, SR¹⁵ or SO₂R¹⁶; R³ is hydrogen, optionally substituted C₁₋₈ alkyl, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₃₋₈ cycloalkenyl, optionally substituted C₆₋₁₀ aryl, optionally substituted heterocycle, or together with R⁵ forms a 10- or 11-membered polycyclic ring which is optionally substituted; R⁴ is hydrogen, optionally substituted C₁₋₈ alkyl,

optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₃₋₈ cycloalkenyl, optionally substituted C₆₋₁₀ aryl, optionally substituted heterocycle, or together with R⁵ forms a spiro monocyclic or polycyclic, carbocyclic or heterocyclic, saturated or unsaturated 5 to 10 member ring which is optionally substituted; R⁵ is hydrogen, optionally substituted C₁₋₈ alkyl, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₃₋₈ cycloalkenyl, optionally substituted C₆₋₁₀ aryl, optionally substituted heterocycle, or together with R⁴ forms a spiro monocyclic or polycyclic carbocyclic or heterocyclic, saturated or unsaturated 5 to 10 member ring which is optionally substituted or together with R³ forms a 5 or 6 member ring which is optionally substituted; R⁶ is halogen, hydrogen, optionally substituted C₁₋₈ alkyl, OR⁹, C(O)R¹⁰, NO₂, NR¹³R¹⁴, CN, SR¹⁵ or SO₂R₁₆; R⁷ is halogen, hydrogen, optionally substituted C₁₋₈ alkyl, OR⁹, C(O)R¹⁰, NO₂, NR¹³R¹⁴, CN, SR¹⁵ or SO₂R¹⁶; R⁸ is halogen, hydrogen, optionally substituted C₁₋₈ alkyl, OR⁹, C(O)R¹⁰, NO₂, NR¹³R¹⁴, CN, SR¹⁵ or SO₂R¹⁶; R⁹ is hydrogen, C(O)(C₁₋₈ alkyl) or optionally substituted C₁₋₈ alkyl; R¹⁰ is hydrogen, optionally substituted C₁₋₈ alkyl, O(C₁₋₈ alkyl), NR¹¹R¹² or OH; R¹¹ is hydrogen, optionally substituted C₆₋₁₀ aryl or optionally substituted C¹⁻⁸ alkyl; R¹² is hydrogen, optionally substituted C₆₋₁₀ aryl or optionally substituted C₁₋₈ alkyl; R¹³ is hydrogen, optionally substituted C₆₋₁₀ aryl or optionally substituted C₁₋₈ alkyl; R¹⁴ is hydrogen, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₈ alkyl, C(O)(C₁₋₈ alkyl) or SO₂(C₁₋₈ alkyl); R¹⁵ is hydrogen, optionally substituted C₁₋₈ alkyl or O(C₁₋₈ alkyl); R¹⁶ is OH, O(C₁₋₈ alkyl), (C₁₋₈ alkyl) or NR¹¹R¹²; R¹⁷ is hydrogen, optionally substituted C₆₋₁₀ aryl or optionally substituted C₁₋₈ alkyl; R¹⁸ is hydrogen, C(O)(C₁₋₈ alkyl), optionally substituted C₆₋₁₀ aryl, or optionally substituted C₁₋₈ alkyl; R¹⁹ is hydrogen, C(O)(C₁₋₈ alkyl), optionally substituted C₆₋₁₀ aryl or optionally substituted C₁₋₈ alkyl; R²⁰ is hydrogen, optionally substituted C₆₋₁₀ aryl or optionally substituted C₁₋₈ alkyl; R²¹ is hydrogen, optionally substituted C₆₋₁₀ aryl or optionally substituted C₁₋₈ alkyl; n is 1, 2, 3, 4, or 5; and m is 1, 2, 3, 4, or
 5. 2. The method according to claim 1, wherein the FPR2 agonist is a compound selected from: 1-(4-bromophenyl)-3-[4-ethyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1-yl]urea; 1-(4-bromophenyl)-3-[4-ethyl-2,5-dioxo-4-(propan-2-yl)imidazolidin-1-yl]urea; 1-(4-bromophenyl)-3-(4,4-diethyl-2,5-dioxoimidazolidin-1-yl)urea; 1-(4-bromo-2-fluorophenyl)-3-(4,4-diethyl-2,5-dioxoimidazolidin-1-yl)urea; 1-(4-bromophenyl)-3-(2,4-dioxo-1,3-diazaspiro[4.5]dec-3-yl)urea; 1-(4-bromophenyl)-3-[4-methyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1-yl]urea; 1-(4-bromophenyl)-3-[4-methyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1-yl]urea; 1-(4-bromo-2-fluorophenyl)-3-[4-ethyl-2,5-dioxo-4-(propan-2-yl)imidazolidin-1-yl]urea; 1-(4-bromophenyl)-3-[2,5-dioxo-4,4-di(propan-2-yl)imidazolidin-1-yl]urea; 1-(4-bromophenyl)-3-(4,4-dicyclopropyl-2,5-dioxoimidazolidin-1-yl)urea; 1-(4-bromophenyl)-3-[4-ethyl-2,5-dioxo-4-(propan-2-yl)imidazolidin-1-yl]urea; 1-(4-bromophenyl)-3-[4-ethyl-2,5-dioxo-4-(propan-2-yl)imidazolidin-1-yl]urea; 1-(4-bromo-2-fluorophenyl)-3-[4-ethyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1-yl]urea; 1-(4-bromophenyl)-3-{4-[2-(furan-2-yl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl}urea; 1-(4-bromophenyl)-3-{4-[2-(4-fluorophenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl}urea; 1-(4-bromophenyl)-3-{4-[2-(3-fluorophenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl}urea; 1-(4-bromophenyl)-3-{4-[2-(4-hydroxyphenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl}urea; 1-(4-bromophenyl)-3-{4-methyl-2,5-dioxo-4-[2-(thiophen-2-yl)ethyl]imidazolidin-1-yl}urea; 1-(4-bromo-2-fluorophenyl)-3-{4-[2-(4-hydroxyphenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl}urea; 1-(4-bromophenyl)-3-{4-methyl-4-[2-(5-methylfuran-2-yl)ethyl]-2,5-dioxoimidazolidin-1-yl}urea; 1-(4-bromo-2-fluorophenyl)-3-{4-[2-(3-fluoro-4-hydroxyphenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl}urea; 1-(4-bromophenyl)-3-{4-[2-(3-fluoro-4-hydroxyphenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl}urea; 1-(4-bromo-2-fluorophenyl)-3-{4-[2-(2-hydroxyphenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl}urea; 1-(4-bromo-2-fluorophenyl)-3-{4-[2-(3-hydroxyphenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl}urea; 1-(4-bromophenyl)-3-{4-[2-(3-hydroxyphenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl}urea; 1-(4-bromophenyl)-3-{4-[2-(2-hydroxyphenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl}urea; 1-(4-bromophenyl)-3-[4-(hydroxymethyl)-2,5-dioxo-4-(propan-2-yl)imidazolidin-1-yl]urea; 2-[1-{[(4-bromophenyl)carbamoyl]amino}-2,5-dioxo-4-(propan-2-yl)imidazolidin-4-yl]-N-(2-hydroxyethyl)acetamide; methyl 2-[2-(1-{[(4-bromophenyl)carbamoyl]amino}-4-ethyl-2,5-dioxoimidazolidin-4-yl)ethyl]benzoate; 2-[1-{[(4-bromophenyl)carbamoyl]amino}-2,5-dioxo-4-(propan-2-yl)imidazolidin-4-yl]-N-(1,3-dihydroxypropan-2-yl)acetamide; 2-[2-(1-{[(4-bromophenyl)carbamoyl]amino}-4-ethyl-2,5-dioxoimidazolidin-4-yl)ethyl]benzoic acid; 2-[2-(1-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4-ethyl-2,5-dioxoimidazolidin-4-yl)ethyl]benzoic acid; 3-({[1-{[(4-bromophenyl)carbamoyl]amino}-2,5-dioxo-4-(propan-2-yl)imidazolidin-4-yl]acetyl}amino)propanoic acid; 2-[1-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-2,5-dioxo-4-(propan-2-yl)imidazolidin-4-yl]-N-(2-hydroxyethyl)acetamide; 2-{2-[1-{[(4-bromophenyl)carbamoyl]amino}-2,5-dioxo-4-(propan-2-yl)imidazolidin-4-yl]ethyl}benzoic acid; diethyl [2-({[1-{[(4-bromophenyl)carbamoyl]amino}-2,5-dioxo-4-(propan-2-yl)imidazolidin-4-yl]acetyl}amino)ethyl]phosphonate; 1-(4-bromophenyl)-3-{4-[2-(2-fluorophenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1-yl}urea; and 3-({[1-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-2,5-dioxo-4-(propan-2-yl)imidazolidin-4-yl]acetyl}amino)propanoic acid.
 3. The method according to claim 1, wherein the FPR2 agonist is a compound is selected from: 1-(4-bromophenyl)-3-[4-ethyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1-yl]urea; 1-(4-bromophenyl)-3-[4-ethyl-2,5-dioxo-4-(propan-2-yl)imidazolidin-1-yl]urea; 1-(4-bromophenyl)-3-(4,4-diethyl-2,5-dioxoimidazolidin-1-yl)urea; 1-(4-bromo-2-fluorophenyl)-3-(4,4-diethyl-2,5-dioxoimidazolidin-1-yl)urea; 1-(4-bromophenyl)-3-(2,4-dioxo-1,3-diazaspiro[4.5]dec-3-yl)urea; 1-(4-bromophenyl)-3-[4-methyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1-yl]urea; 1-(4-bromo-2-fluorophenyl)-3-[4-ethyl-2,5-dioxo-4-(propan-2-yl)imidazolidin-1-yl]urea; 1-(4-bromophenyl)-3-[2,5-dioxo-4,4-di(propan-2-yl)imidazolidin-1-yl]urea; and 1-(4-bromophenyl)-3-(4,4-dicyclopropyl-2,5-dioxoimidazolidin-1-yl)urea.
 4. The method of claim 1, wherein the FPR2 agonist is 1-(4-bromophenyl)-3-[4-ethyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1-yl]urea.
 5. The method of claim 1, wherein the FPR2 agonist is 1-(4-bromophenyl)-3-[4-ethyl-2,5-dioxo-4-(propan-2-y dazolidin-1-yl]urea.
 6. The method of claim 1, wherein the FPR2 agonist is 1-(4-bromophenyl)-3-(4,4-diethyl-2,5-dioxoimidazolidin-1-yl)urea.
 7. The method of claim 1, wherein the FPR2 agonist is 1-(4-bromo-2-fluorophenyl)-3-(4,4-diethyl-2,5-dioxoimidazolidin-1-yl)urea.
 8. The method of claim 1, wherein the FPR2 agonist is 1-(4-bromophenyl)-3-(2,4-dioxo-1,3-diazaspiro[4.5]dec-3-yl)urea.
 9. The method of claim 1, wherein the FPR2 agonist is 1-(4-bromophenyl)-3-[4-methyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1-yl]urea.
 10. The method of claim 1, wherein the FPR2 agonist is 1-(4-bromo-2-fluorophenyl)-3-[4-ethyl-2,5-dioxo-4-(propan-2-yl)imidazolidin-1-yl]urea.
 11. The method of claim 1, wherein the FPR2 agonist is 1-(4-bromophenyl)-3-[2,5-dioxo-4,4-di(propan-2-yl)imidazolidin-1-yl]urea.
 12. The method of claim 1, wherein the FPR2 agonist is 1-(4-bromophenyl)-3-(4,4-dicyclopropyl-2,5-dioxoimidazolidin-1-yl)urea.
 13. The method according to claim 1, wherein the FPR2 agonist is a compound selected from: 1-(4-chlorophenyl)-3-(2,4-dioxo-1,3-diazaspiro[4,5]decan-3-yl) urea; 1-(4-chlorophenyl)-3-(4-ethyl-4-methyl-2,5-dioxoimidazolidin-1-yl)urea; and 1-(8-methyl-2,4-dioxo-1,3-diazaspiro[4,5]decan-3-yl)-3-(p-tolyl)urea.
 14. The method according to claim 1, wherein the FPR2 agonist is a compound selected from: (+) 1-(4-bromophenyl)-3-[4-methyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1-yl]urea; (+)1-(4-bromophenyl)-3-[4-ethyl-2,5-dioxo-4-(propan-2-yl)imidazolidin-1-yl]urea; (−)1-(4-bromophenyl)-3-[4-ethyl-2,5-dioxo-4-(propan-2-yl)imidazolidin-1-yl]urea; and ethyl 3-[1-{[(4-bromophenyl)carbamoyl]amino}-2,5-dioxo-4-(propan-2-yl)imidazolidin-4-yl]propanoate.
 15. A method of treating an ocular inflammatory disease in a subject in need of such treatment, wherein the method comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one formyl peptide receptor 2 (FPR2) agonist to the subject; wherein the ocular inflammatory disease is selected from the group consisting of uveitis, dry eye, keratitis, allergic eye disease, infectious keratitis, herpetic keratitis, corneal angiogenesis, lymphangiogenesis, retinitis, choroiditis, acute multifocal placoid pigment epitheliopathy, Behcet's disease, post-surgical corneal wound healing, wet age-related macular degeneration (ARMD) and dry ARMD; and wherein the FPR2 agonist is a compound is selected from the group consisting of: ethyl 3-{[(4-bromophenyl)carbamoyl]amino}-2,4-dioxo-1,3-diazaspiro[4.5]decane-8- carboxylate; 1-[4-methyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1-yl]-3-phenylurea; and 1-(2-fluorophenyl)-3-[4-methyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1-yl]urea.
 16. The method of claim 1, wherein the ocular inflammatory disease is dry eye.
 17. The method of claim 15, wherein the ocular inflammatory disease is dry eye. 